<SEC-DOCUMENT>0001628280-23-007952.txt : 20230315
<SEC-HEADER>0001628280-23-007952.hdr.sgml : 20230315
<ACCEPTANCE-DATETIME>20230315073901
ACCESSION NUMBER:		0001628280-23-007952
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		18
CONFORMED PERIOD OF REPORT:	20230315
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20230315
DATE AS OF CHANGE:		20230315

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CUMBERLAND PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0001087294
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33637
		FILM NUMBER:		23733296

	BUSINESS ADDRESS:	
		STREET 1:		2525 WEST END AVENUE
		STREET 2:		SUITE 950
		CITY:			NASHVILLE,
		STATE:			TN
		ZIP:			37203
		BUSINESS PHONE:		615-255-0068

	MAIL ADDRESS:	
		STREET 1:		2525 WEST END AVENUE
		STREET 2:		SUITE 950
		CITY:			NASHVILLE
		STATE:			TN
		ZIP:			37203
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>cpix-20230315.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:17a4ed2a-c2d2-43f2-9464-8c3c14b2e41e,g:721154ad-efcd-42f7-ac9d-ad1391d8efec,d:dc04fc043b5d43fc803462b4943fba77--><html xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>cpix-20230315</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i78615fa2d7f041369df685fcd4430c86_D20230315-20230315" name="dei:EntityCentralIndexKey" id="f-22">0001087294</ix:nonNumeric><ix:nonNumeric contextRef="i78615fa2d7f041369df685fcd4430c86_D20230315-20230315" name="dei:AmendmentFlag" id="f-23">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="cpix-20230315.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i78615fa2d7f041369df685fcd4430c86_D20230315-20230315"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-15</xbrli:startDate><xbrli:endDate>2023-03-15</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="idc04fc043b5d43fc803462b4943fba77_1"></div><div style="min-height:29.25pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:174%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:144%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:144%">FORM <ix:nonNumeric contextRef="i78615fa2d7f041369df685fcd4430c86_D20230315-20230315" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric> </span></div><div style="margin-top:11pt;padding-left:108pt;padding-right:108pt;text-align:center"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i78615fa2d7f041369df685fcd4430c86_D20230315-20230315" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">March 15, 2023</ix:nonNumeric> (March 9, 2023)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Date of Report (date of earliest event reported)</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:144%"><ix:nonNumeric contextRef="i78615fa2d7f041369df685fcd4430c86_D20230315-20230315" name="dei:EntityRegistrantName" id="f-3">CUMBERLAND PHARMACEUTICALS INC.</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:144%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.057%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.742%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.742%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.059%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i78615fa2d7f041369df685fcd4430c86_D20230315-20230315" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-4">Tennessee</ix:nonNumeric></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%"><ix:nonNumeric contextRef="i78615fa2d7f041369df685fcd4430c86_D20230315-20230315" name="dei:EntityFileNumber" id="f-5">001-33637</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i78615fa2d7f041369df685fcd4430c86_D20230315-20230315" name="dei:EntityTaxIdentificationNumber" id="f-6">62-1765329</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(State or other jurisdiction of incorporation or organization)</span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Commission File Number)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(I.R.S. Employer Identification No.)</span></div></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%"><ix:nonNumeric contextRef="i78615fa2d7f041369df685fcd4430c86_D20230315-20230315" name="dei:EntityAddressAddressLine1" id="f-7">2525 West End Avenue, Suite 950</ix:nonNumeric> <ix:nonNumeric contextRef="i78615fa2d7f041369df685fcd4430c86_D20230315-20230315" name="dei:EntityAddressCityOrTown" id="f-8">Nashville</ix:nonNumeric>, <ix:nonNumeric contextRef="i78615fa2d7f041369df685fcd4430c86_D20230315-20230315" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-9">Tennessee</ix:nonNumeric> <ix:nonNumeric contextRef="i78615fa2d7f041369df685fcd4430c86_D20230315-20230315" name="dei:EntityAddressPostalZipCode" id="f-10">37203</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">(Address of Principal Executive Offices)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">(<ix:nonNumeric contextRef="i78615fa2d7f041369df685fcd4430c86_D20230315-20230315" name="dei:CityAreaCode" id="f-11">615</ix:nonNumeric>) <ix:nonNumeric contextRef="i78615fa2d7f041369df685fcd4430c86_D20230315-20230315" name="dei:LocalPhoneNumber" id="f-12">255-0068</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Registrant's telephone number, including area code</span></div><div style="padding-left:5.62pt;padding-right:5.62pt;text-align:center"><span><br/></span></div><div style="padding-left:5.62pt;padding-right:5.62pt;text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</span></div><div><span><br/></span></div><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i78615fa2d7f041369df685fcd4430c86_D20230315-20230315" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="f-13">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt"><span><br/></span></div><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i78615fa2d7f041369df685fcd4430c86_D20230315-20230315" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="f-14">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </span></div><div><span><br/></span></div><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i78615fa2d7f041369df685fcd4430c86_D20230315-20230315" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="f-15">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </span></div><div><span><br/></span></div><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i78615fa2d7f041369df685fcd4430c86_D20230315-20230315" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="f-16">&#9744;</ix:nonNumeric></span><span style="color:#231f20;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act: </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:33.504%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.160%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.036%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i78615fa2d7f041369df685fcd4430c86_D20230315-20230315" name="dei:Security12bTitle" id="f-17">Common Stock, no par value</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i78615fa2d7f041369df685fcd4430c86_D20230315-20230315" name="dei:TradingSymbol" id="f-18">CPIX</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i78615fa2d7f041369df685fcd4430c86_D20230315-20230315" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-19">NASDAQ Global Select Market</ix:nonNumeric></span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div><div><span><br/></span></div><div><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i78615fa2d7f041369df685fcd4430c86_D20230315-20230315" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="f-20">&#9744;</ix:nonNumeric></span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <ix:nonNumeric contextRef="i78615fa2d7f041369df685fcd4430c86_D20230315-20230315" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="f-21">&#9744;</ix:nonNumeric></span></div><div style="height:24.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="idc04fc043b5d43fc803462b4943fba77_4"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(e) Compensatory Arrangements of Certain Officers</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 8, 2023, Cumberland Pharmaceuticals Inc. (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) entered into new employment agreements with each of A.J. Kazimi, the Company&#8217;s Chief Executive Officer (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Kazimi Employment Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), James Herman, the Company&#8217;s Executive Vice President, National Accounts and Chief Compliance Officer (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Herman Employment Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,&#8221;), Todd Anthony, the Company's Vice President of Organizational Development (the "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Anthony Employment Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">"), Chris Bitterman, the Company's Vice President of Sales and Marketing (the "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Bitteman Employment Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">"), and John Hamm, the Company&#8217;s Senior Director of Finance and Accounting and Chief Financial Officer (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Hamm Employment Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), and together with the Kazimi Employment Agreement, the Herman Employment Agreement, the Anthony Employment Agreement, the Bitterman Employment Agreement and the Hamm Agreement, the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Employment Agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). The Employment Agreements were effective as of January 1, 2023. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employment Agreements</span></div><div style="margin-top:8pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each Employment Agreement provides for a salary for services performed, a potential annual bonus and an equity award pursuant to a stock option agreement.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Under the terms of each Employment Agreement, employment is at-will and may be terminated by the employee or the Company at any time, with or without notice and with or without cause. Similarly, each of Mr. Kazimi, Mr. Herman, Mr. Anthony, Mr. Bitterman, and Mr. Hamm may terminate his respective employment with the Company at any time, with or without notice. The Employment Agreements do not provide for any severance payments in the event employment is terminated for cause nor any severance benefits in the event employment is terminated as a result of death or permanent disability. The Employment Agreements include non-competition, non-solicitation and non-disclosure covenants on the part of employees. The Employment Agreements impose obligations regarding confidential information and state that any discoveries or improvements conceived, developed or otherwise made by the employees, or with others, that relate in any way to the Company&#8217;s present or planned business or products, are deemed the Company&#8217;s sole property. The Employment Agreements do not contain any termination or change in control provisions.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Kazimi Employment Agreement</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Kazimi Employment Agreement, Mr. Kazimi will serve as the Company&#8217;s Chief Executive Officer and will receive a base salary of $675,000.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The foregoing descriptions of the Kazimi Employment Agreement are qualified in their entirety by reference to the Kazimi Employment Agreement, is incorporated by reference into this Item. The foregoing description of the Kazimi Employment Agreement does not purport to be complete and is qualified in its entirety by reference to such exhibit.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Herman Employment Agreement</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Herman Employment Agreement, Mr. Herman will serve as the Company&#8217;s Executive Vice President, National Accounts and Chief Compliance Officer and will receive a base salary of $310,000.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The foregoing descriptions of the Herman Employment Agreement are qualified in their entirety by reference to the Herman Employment Agreement, is incorporated by reference into this Item. The foregoing description of the Herman Employment Agreement does not purport to be complete and is qualified in its entirety by reference to such exhibit.</span></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Anthony Employment Agreement</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Anthony Employment Agreement, Mr. Anthony will serve as the Company&#8217;s Vice President of Organizational Development and will receive a base salary of $272,500.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The foregoing descriptions of the Anthony Employment Agreement are qualified in their entirety by reference to the Anthony Employment Agreement, is incorporated by reference into this Item. The foregoing description of the Anthony Employment Agreement does not purport to be complete and is qualified in its entirety by reference to such exhibit.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Bitterman Employment Agreement</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Bitterman Employment Agreement, Mr. Bitterman will serve as the Company&#8217;s Vice President of Sales and Marketing and will receive a base salary of $258,500.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The foregoing descriptions of the Bitterman Employment Agreement are qualified in their entirety by reference to the Bitterman Employment Agreement,  is incorporated by reference into this Item. The foregoing description of the Bitterman Employment Agreement does not purport to be complete and is qualified in its entirety by reference to such exhibit.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Hamm Employment Agreement</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Hamm Employment Agreement, Mr. Hamm will serve as the Company&#8217;s Senior Director of Finance and Accounting and Chief Financial Officer and will receive a base salary of $228,000.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The foregoing descriptions of the Hamm Employment Agreement are qualified in their entirety by reference to the Hamm Employment Agreement, is incorporated by reference into this Item. The foregoing description of the Hamm Employment Agreement does not purport to be complete and is qualified in its entirety by reference to such exhibit.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.01 Financial Statements and Exhibits</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.228%"><tr><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.883%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.478%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Exhibit No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Description</span></td></tr><tr style="height:11pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10.11</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="ajkazimiemploymentagreemen.htm">Employment Agreement dated March 9, 2023, effective as of January 1, 2023, by and between A.J. Kazimi and Cumberland Pharmaceuticals Inc.</a></span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10.12</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="jameshermanemploymentagree.htm">Employment Agreement dated March 9, 2023, effective as of January 1, 2023, by and between Jim Herman and Cumberland Pharmaceuticals Inc. </a></span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10.13</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="toddanthony-employmentagre.htm">Employment Agreement dated March 9, 2023, effective as of January 1, 2023, by and between Todd Anthony and Cumberland Pharmaceuticals Inc.</a></span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10.14</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="chrisbittermanemploymentag.htm">Employment Agreement dated March 9, 2023, effective as of January 1, 2023, by and between Chris Bitterman and Cumberland Pharmaceuticals Inc. </a></span></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10.15</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="johnhammemploymentagreemen.htm">Employment Agreement dated March 9, 2023, effective as of January 1, 2023, by and between John M. Hamm and Cumberland Pharmaceuticals Inc. </a></span></div></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">(d)  Exhibits</span></div><div><span><br/></span></div><div style="margin-top:11.25pt;text-align:center"><span><br/></span></div><div style="margin-top:11.25pt;text-align:center"><span><br/></span></div><div><span><br/></span></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div id="idc04fc043b5d43fc803462b4943fba77_7"></div><div style="margin-top:11.25pt;text-align:center"><span><br/></span></div><div style="margin-top:11.25pt;text-align:center"><span><br/></span></div><div style="margin-top:11.25pt;text-align:center"><span><br/></span></div><div style="margin-top:11.25pt;text-align:center"><span><br/></span></div><div style="margin-top:11.25pt;text-align:center"><span><br/></span></div><div style="margin-top:11.25pt;text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:11.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:11.25pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="margin-top:16.25pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:24.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.234%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.234%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.386%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cumberland Pharmaceuticals Inc.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated: March 15, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">/s/ John Hamm</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">John Hamm</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>2
<FILENAME>cpix-20230315.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:17a4ed2a-c2d2-43f2-9464-8c3c14b2e41e,g:721154ad-efcd-42f7-ac9d-ad1391d8efec-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:cpix="http://cumberlandpharma.com/20230315" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://cumberlandpharma.com/20230315">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021" schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cpix-20230315_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cpix-20230315_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="DocumentandEntityInformationDocument" roleURI="http://cumberlandpharma.com/role/DocumentandEntityInformationDocument">
        <link:definition>0000001 - Document - Document and Entity Information Document</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>3
<FILENAME>cpix-20230315_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:17a4ed2a-c2d2-43f2-9464-8c3c14b2e41e,g:721154ad-efcd-42f7-ac9d-ad1391d8efec-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_PreCommencementTenderOffer_1c94e26d-6aad-4caf-b205-7eea79b87d7b_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_bee2e079-188a-4ddf-b180-dbbb8cf55f45_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_570b2fae-6c76-4ce1-9445-d7e9c5c36687_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_a0ef6f4b-b3c8-46e1-96d0-0b6539fec598_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_78eea00c-3246-4a79-9df6-923b0457ef3d_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_f51cf2e3-0949-49b3-b303-2bb26cc3e671_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_d00a7634-ac22-41e2-8970-330e83f7e316_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_e30edb1e-7301-4543-99a1-c8974104d75e_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_50740dd2-41a9-4210-b4d2-caa9eae051e9_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_2ed3f7ff-2f5b-42c7-9118-71ced87cdf6d_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_c3e51cf3-af73-4bed-ad7e-4f56ed4e8727_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_0b6ab198-8524-4808-945a-5e6ab2710097_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_02d28b9f-c813-48fd-9695-a76f02105134_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_5b357638-cfa1-4435-b944-74b5681fe7a5_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_fa4f2a4a-949e-40aa-9977-f0ccff854abb_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_7e54cc63-d864-41ed-9649-66920940dee8_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_c31b407b-4308-42ae-beee-93e5bb955da5_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_4f50ff0a-55cc-4b5e-9f68-20378ae229f7_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_c430ba51-5c46-4267-a9d0-9ce8bababc5d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_2e52a925-35cb-43f7-a5f4-e23d9f3a5b64_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_541fab52-2b9f-45d0-9e18-28c93422e7bc_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_b5bf6b6b-ee9f-4108-a870-cda320837c1e_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_e1af54c4-c5a8-4c0d-b4da-29ab7d487d06_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>4
<FILENAME>cpix-20230315_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:17a4ed2a-c2d2-43f2-9464-8c3c14b2e41e,g:721154ad-efcd-42f7-ac9d-ad1391d8efec-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://cumberlandpharma.com/role/DocumentandEntityInformationDocument" xlink:type="simple" xlink:href="cpix-20230315.xsd#DocumentandEntityInformationDocument"/>
  <link:presentationLink xlink:role="http://cumberlandpharma.com/role/DocumentandEntityInformationDocument" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_20e00b42-7deb-4f9b-b471-4a5765029ae5" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_23e71eb8-0d44-43ad-8e7a-f5f0f200ac2b" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_20e00b42-7deb-4f9b-b471-4a5765029ae5" xlink:to="loc_dei_DocumentType_23e71eb8-0d44-43ad-8e7a-f5f0f200ac2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_98fe87c8-72dd-4404-b7c6-d57d2babb233" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_20e00b42-7deb-4f9b-b471-4a5765029ae5" xlink:to="loc_dei_DocumentPeriodEndDate_98fe87c8-72dd-4404-b7c6-d57d2babb233" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_7c1faba2-37cd-42d7-85a1-109261e3521a" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_20e00b42-7deb-4f9b-b471-4a5765029ae5" xlink:to="loc_dei_EntityRegistrantName_7c1faba2-37cd-42d7-85a1-109261e3521a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_83377e45-f9e3-4cb5-b8fc-580ddaf0731c" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_20e00b42-7deb-4f9b-b471-4a5765029ae5" xlink:to="loc_dei_EntityCentralIndexKey_83377e45-f9e3-4cb5-b8fc-580ddaf0731c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_26440f48-e715-4f93-b82a-d8538ebd8293" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_20e00b42-7deb-4f9b-b471-4a5765029ae5" xlink:to="loc_dei_AmendmentFlag_26440f48-e715-4f93-b82a-d8538ebd8293" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_51743658-58d6-4cd8-b4ba-8cf415853bb7" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_20e00b42-7deb-4f9b-b471-4a5765029ae5" xlink:to="loc_dei_EntityIncorporationStateCountryCode_51743658-58d6-4cd8-b4ba-8cf415853bb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_a15719e9-85b1-4217-be93-567d6a4a9ca5" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_20e00b42-7deb-4f9b-b471-4a5765029ae5" xlink:to="loc_dei_EntityFileNumber_a15719e9-85b1-4217-be93-567d6a4a9ca5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_44ce14ad-3af5-46d2-9fac-a2009b017cb7" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_20e00b42-7deb-4f9b-b471-4a5765029ae5" xlink:to="loc_dei_EntityTaxIdentificationNumber_44ce14ad-3af5-46d2-9fac-a2009b017cb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_b7667914-d682-4006-9c99-9d01699f9b22" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_20e00b42-7deb-4f9b-b471-4a5765029ae5" xlink:to="loc_dei_CityAreaCode_b7667914-d682-4006-9c99-9d01699f9b22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_117647b5-34e8-4043-a78b-bcf4c8ded702" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_20e00b42-7deb-4f9b-b471-4a5765029ae5" xlink:to="loc_dei_LocalPhoneNumber_117647b5-34e8-4043-a78b-bcf4c8ded702" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_5e7bd424-b228-4069-a6ee-65de65e0af08" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_20e00b42-7deb-4f9b-b471-4a5765029ae5" xlink:to="loc_dei_WrittenCommunications_5e7bd424-b228-4069-a6ee-65de65e0af08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_4a728f8f-2f01-4072-bd79-fec269e30039" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_20e00b42-7deb-4f9b-b471-4a5765029ae5" xlink:to="loc_dei_SolicitingMaterial_4a728f8f-2f01-4072-bd79-fec269e30039" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_7b6e9ce2-22bc-4d7c-805f-177cd46e6ce9" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_20e00b42-7deb-4f9b-b471-4a5765029ae5" xlink:to="loc_dei_PreCommencementTenderOffer_7b6e9ce2-22bc-4d7c-805f-177cd46e6ce9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_f6927867-68d6-4db8-b74f-21c31e0b2d94" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_20e00b42-7deb-4f9b-b471-4a5765029ae5" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_f6927867-68d6-4db8-b74f-21c31e0b2d94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_1a6fc9ba-5900-408f-81d9-116a244a4bb5" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_20e00b42-7deb-4f9b-b471-4a5765029ae5" xlink:to="loc_dei_Security12bTitle_1a6fc9ba-5900-408f-81d9-116a244a4bb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_4db08772-bd81-42b9-b7c4-8793e278e985" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_20e00b42-7deb-4f9b-b471-4a5765029ae5" xlink:to="loc_dei_TradingSymbol_4db08772-bd81-42b9-b7c4-8793e278e985" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_50d96d95-f85a-4934-86cb-cb21fd7c53ae" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_20e00b42-7deb-4f9b-b471-4a5765029ae5" xlink:to="loc_dei_SecurityExchangeName_50d96d95-f85a-4934-86cb-cb21fd7c53ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_7b31a34b-dfe5-47d9-aa5c-9f288a44cec2" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_20e00b42-7deb-4f9b-b471-4a5765029ae5" xlink:to="loc_dei_EntityEmergingGrowthCompany_7b31a34b-dfe5-47d9-aa5c-9f288a44cec2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_219cc2f6-93c4-412a-a67a-737b13629bc4" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_20e00b42-7deb-4f9b-b471-4a5765029ae5" xlink:to="loc_dei_EntityAddressAddressLine1_219cc2f6-93c4-412a-a67a-737b13629bc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_55a75665-55b1-4ad7-aa13-449591772bbf" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_20e00b42-7deb-4f9b-b471-4a5765029ae5" xlink:to="loc_dei_EntityAddressPostalZipCode_55a75665-55b1-4ad7-aa13-449591772bbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_5f7e14ba-2b7c-4e1e-b965-13ba83c1339b" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_20e00b42-7deb-4f9b-b471-4a5765029ae5" xlink:to="loc_dei_EntityAddressCityOrTown_5f7e14ba-2b7c-4e1e-b965-13ba83c1339b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_f590a54c-b657-423f-a9db-891addfdc50c" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_20e00b42-7deb-4f9b-b471-4a5765029ae5" xlink:to="loc_dei_EntityAddressStateOrProvince_f590a54c-b657-423f-a9db-891addfdc50c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.11
<SEQUENCE>5
<FILENAME>ajkazimiemploymentagreemen.htm
<DESCRIPTION>EX-10.11
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i506476fa67154df1b840737594e55713_1"></div><div style="min-height:153.36pt;width:100%"><div style="text-align:center"><img alt="image_0.jpg" src="image_0.jpg" style="height:90px;margin-bottom:5pt;vertical-align:text-bottom;width:394px"></div><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">March 9, 2023</font></div><div style="text-align:justify"><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Mr. A.J. Kazimi </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1600 West End Avenue, Suite 1300</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Nashville, TN  37203</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Re&#58;&#160;&#160;&#160;&#160;Employment of AJ Kazimi as Chief Executive Officer by Cumberland Pharmaceuticals Inc.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Dear AJ, </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Effective January 1, 2023, this letter agreement (the &#8220;Agreement&#8221;) will evidence the terms and conditions under which you will be employed by Cumberland Pharmaceuticals Inc. (the &#8220;Company&#8221;) In consideration of your appointment as Chief Executive Officer of the Company, and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties agree as follows&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Compensation.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  The Company agrees to compensate you as follows&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;The Company agrees to pay you on a salary basis for services performed based on an annual rate of six hundred thirty-five thousand dollars ($675,000.00), payable in arrears in equal monthly installments on the 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> day of each calendar month of 2023.  For each year, thereafter, you will be paid on a salary basis for services performed based on an annual rate determined by the Company in its sole discretion&#59; provided, however, that any obligation to make payments under this Section 1(a) will cease upon termination of your employment for any reason.  Notwithstanding the foregoing, nothing in this Section 1(a) alters or is intended to alter the at-will nature of your employment as described in Section 3 of this Agreement.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;You will be eligible to participate in any Company-wide employee benefits as approved by the Board of Directors.  The terms of your eligibility and participation will be governed by the provisions of the employee benefit plans, as such plans may be amended from time to time in the discretion of the Company's Board of Directors.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;You may be eligible for any Company bonus program, based upon performance in meeting your individual objectives and the Company&#8217;s overall performance, both as determined and approved by the Board of Directors of the Company.  Any such bonus will be discretionary and will be subject to the terms of the applicable bonus program, the terms of which program may be modified from year to year in the sole discretion of the Company&#8217;s Board of Directors.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:100.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:153.36pt;width:100%"><div><font><br></font></div></div><div style="padding-right:-4.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;You will receive a grant of Cumberland Pharmaceuticals common stock, pursuant to a stock options agreement (SOA).  Such shares will be subject to the SOA and the terms set forth in the incentive compensation plan under which they are awarded.  You may, at the Company&#8217;s sole discretion, receive additional awards of Company equity, which will be subject to their designated agreements and the incentive compensation plans under which they are awarded.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)&#160;&#160;&#160;&#160;Except as set forth in Section 2, the Company shall not be liable to you for any expense incurred by you unless you receive the Company's prior written consent to reimburse you for such expense.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:4.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Additional Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. During the term hereof, you shall be entitled to receive prompt reimbursement for all reasonable and documented expenses incurred in the performance of services in accordance with the expense reimbursement policy of the Company.  Such reimbursement policy shall require adequate documentation by you of the expenses and payment by the Company of such amounts shall be made within a reasonable period after the close of the year in which the expenses were incurred.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Employment at Will</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.   This Agreement is not intended to and shall not be understood in any manner as affecting or modifying the at-will status of your employment with the Company.  As an at-will employee either you or the Company may terminate the employment relationship at any time with or without cause or notice.  The obligations of Sections 4, 5, 6, 7, 8, 10, 11 and 12 herein shall survive the termination of the employment relationship or of this Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Confidentiality</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  All knowledge and information, not already available to the public, which you acquire, have acquired, or will acquire in the course of your employment with the Company with respect to the Company&#8217;s business, work methods, or pending regulatory matters, or other Company matters that are treated by the Company as confidential, shall be regarded by you as trade secrets, whether or not they are classifiable legally as trade secrets, and shall be treated by you as strictly confidential.  Such knowledge and information shall not either directly or indirectly be used, disclosed, or made accessible to anyone by you for any purpose, except in the ordinary course of the Company&#8217;s business under circumstances in which you are authorized to use or disclose such information.  No disclosures of such confidential information shall be made outside of those you are authorized to make in the regular and ordinary course of your duties unless and until you receive prior written permission of the Board of Directors of the Company to make such disclosure.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 5.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Discoveries and Improvements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  During the time that you are employed by the Company, all confidential information, trade secrets, or proprietary information and all other discoveries, inventions, software programs, processes, methods and improvements that are conceived, developed, or otherwise made by you , alone or with others, that relate in any way to the Company&#8217;s present or planned business or products (collectively the &#8220;Developments&#8221;), whether or not patentable or subject to copyright protection and whether or not reduced to tangible form or reduced to practice, shall be the sole property of the Company.  You agree to disclose all Developments promptly, fully and in writing to the Company.  You agree to keep and maintain </font></div><div style="height:100.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:153.36pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">adequate and current dated and witnessed written records of all such Developments, in the form of notes, sketches, drawings, or reports, which records shall  be promptly submitted to the Company and shall be and remain the property of the Company at all times.  You agree to assign, and hereby do assign, to, the Company all your right, title and interest throughout the world in and to all Developments.  You agree that all Developments shall constitute &#8220;Works for Hire&#8221; (as such are defined under the U.S. Copyright Laws) and hereby assign to the Company all copyrights, patents and other proprietary rights you may have in any Developments without any obligation on the part of the Company to pay royalties or any other consideration to you for such Developments.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 6.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Publication</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  All documents and other writings produced by you during the period of your employment, which relate to work you are doing or have done for the Company or to the business of the Company or its affiliates, shall belong to the Company.  You will not publish outside of the Company any such writing without the prior written consent of the Board of Directors of the Company.  You will, without further compensation, execute at any time (whether or not you are still employed by the Company) all documents requested of you relating to the protection of such rights, including the assignment of such rights to the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Litigation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You shall notify the Company within three business days if no longer employed and immediately if still employed by the Company if you are contacted by any person relating to any claim or litigation against the Company.  You shall not communicate in any manner with any person related to any claim or litigation against the Company without the prior consent of the Board of Directors of the Company unless compelled to do so by law.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Competition</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.   For so long as you are employed by the Company or any Affiliate (as defined below) and for a period of one year after you cease to be employed by the Company or any Affiliate, you shall not, directly or indirectly, engage in any work or other activity--whether as owner, stockholder, partner, officer, consultant, or otherwise--involving a trademark, product, or process that, in the opinion of the Company&#8217;s Chief Executive Officer, is  similar to a trademark, product or process on which you worked for the Company (or any Affiliate) or obtained knowledge about while working for the Company at any time during the period of employment, if such work or other activity is then, or reasonably expected to become, competitive with that of the Company (or any Affiliate).  The restriction in the preceding sentence shall not apply if you have disclosed to the Company in writing all the known facts relating to such work or activity and have received a release in writing from the Board of Directors of the Company allowing you to engage in such work or activity. The Company&#8217;s Chief Executive Officer shall have sole discretion to determine whether your work or activity for another employer involves trademarks, products, or processes that are similar to trademarks, products, or processes that you worked on for the Company. Ownership by you of five percent (5%) or less of the outstanding shares of stock of any company either (i) listed on a national securities exchange, or (ii) having at least one hundred (100) stockholders shall not make you a &#8220;stockholder&#8221; within the meaning of that term as used in this paragraph.  For one year after you cease to work for the Company, you will not engage in any work or activity that will cause you to inevitably disclose to anyone not employed by the Company (or an Affiliate) any trade secret </font></div><div style="height:100.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:153.36pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or confidential information that belongs to the Company or one of its Affiliates.   Nothing in this paragraph shall limit the rights or remedies of the Company arising, directly or indirectly, from such competitive employment, including, without limitation, claims based upon breach of fiduciary duty, misappropriation, or theft of confidential information.  The term &#8220;Affiliate&#8221; shall mean the Company and any entity controlling, controlled by, or under common control with the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Conflicting Contracts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You represent and warrant that you are not now under any obligation resulting from any contract or arrangement, to any person, firm, or corporation, which is inconsistent or in conflict with this Agreement.  Likewise you represent and warrant that you are not now under any obligation resulting from any contract or arrangement to any person, firm, or corporation which would prevent, limit, or impair in any way the performance by you of your obligations to the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Solicitation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  After you cease to be employed by the Company (or a Company affiliate)&#58; </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;You agree not to solicit, directly or indirectly, business related to the development or sales of pharmaceutical products from any entity, organization, or person which is contracted with the Company, which has been doing business with the Company or from which the Company was soliciting at the time of your termination, or a firm which you knew or had reason to know that the Company was going to solicit business at the time you ceased to be employed by the Company.&#160; The restriction set forth in the preceding sentence shall not apply if you have disclosed to the Company in writing all the known facts relating to such solicitation and have received a release in writing from the Board of Directors of the Company to engage in such solicitation.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;You agree not to solicit, recruit, hire, or assist in the hiring of any employee of the Company to work for you or another person, firm, corporation, or business.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Return of Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Upon termination of your employment for any reason, you shall immediately return to the Company all documents and things belonging to the Company.  This includes, but is not limited to, trade secrets, confidential information, knowledge, data or know-how, and software containing such information, whether or not the documents are marked &#8220;Confidential.&#8221;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Remedies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You acknowledge that in the event of breach of this Agreement by you, actual damages to the Company will be impossible to calculate, the Company&#8217;s remedies at law will be inadequate, and the Company will suffer irreparable harm.  Therefore, you agree that any of the covenants contained in this Agreement may be specifically enforced through injunctive relief, but such right to injunctive relief shall not preclude the Company from other remedies which may be available to it.  You further agree that should you fail to keep any of the promises made by you in this Agreement, or any way violate this Agreement, the Company shall be entitled to recover all monies the Company is required to spend, including attorneys&#8217; fees, to enforce the provisions of this Agreement.</font></div><div style="height:100.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:153.36pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Best Efforts and Conflicts of Interest</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58;  You are hired with the understanding that Cumberland is your sole employer and you will provide a full-time work effort. You agree to devote your entire professional and business-related time and best efforts t&#92;o the services required of you by the express and implicit terms of this Agreement, to the reasonable satisfaction of Cumberland in its sole and complete discretion.  Engaging in activities outside of work that create a conflict of interest, or detract from your ability to perform your assigned responsibilities or meet your defined goals and objectives with Cumberland, is a problem and may lead to disciplinary action up to and including termination of employment.  If you believe that you are potentially involved in a situation that could create a conflict of interest and affect your ability to adequately perform your job with&#160;Cumberland, you should inform your direct supervisor and Cumberland&#8217;s Human Resources Department immediately.</font></div><div style="height:100.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i506476fa67154df1b840737594e55713_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Standards of Business Conduct and Ethics.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Cumberland&#8217;s commitment to a culture of integrity, ethics and compliance with the law is comprised in this policy, which will be provided to you as part of the conditions of your employment. You will have the opportunity to read, discuss and understand this policy prior to accepting and signing its Letter of Agreement.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">15.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Debarment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You represent and warrant that you have not been debarred and will notify the Company immediately if you are debarred, pursuant to subsection 306(a) or 306(b) of the Federal Food, Drug, and Cosmetic Act.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 16.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Any notice required or permitted to be given under this Agreement shall be sufficient if in writing and if sent by registered or certified mail to your residence or to the Company&#8217;s principal office in the case of the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 17&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The waiver by either party of any provision of this Agreement shall not operate or be construed as a waiver of any subsequent breach.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 18.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Entire Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement contains the entire agreement of the parties and may not be changed orally, but only by an agreement in writing signed by the party against whom enforcement of any waiver, change, modification, extension, or discharge is sought.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 19.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Governance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement shall be governed by the laws of the State of Tennessee.  Any dispute arising out of this Agreement shall be resolved, at the Company&#8217;s sole option, by courts sitting in Nashville, Tennessee, and you waive any objection to such venue.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 20.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Enforceability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In the event that any provision of this Agreement shall be held by a court to be unenforceable, such provision will be enforced to the maximum extent permissible, and the remaining portions of this Agreement shall remain in full force and effect.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">21.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Survival</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding any termination of your employment, this Agreement shall survive and remain in effect in accordance with its terms.</font></div><div style="padding-left:3pt;text-align:justify"><font><br></font></div><div style="padding-left:3pt;text-align:justify"><font><br></font></div><div style="padding-left:1.5pt;padding-right:1.5pt;text-align:center"><font><br></font></div><div style="padding-left:1.5pt;padding-right:1.5pt;text-align:center"><font><br></font></div><div style="padding-left:1.5pt;padding-right:1.5pt;text-align:center"><font><br></font></div><div style="padding-left:1.5pt;padding-right:1.5pt;text-align:center"><font><br></font></div><div style="padding-left:1.5pt;padding-right:1.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">#   #   #   #</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This letter agreement may be signed in one or more counterparts, each of which shall be an original and all of which will constitute one and the same instrument.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:216pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:216pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Sincerely yours,</font></div><div style="padding-left:216pt;text-align:justify"><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> CUMBERLAND PHARMACEUTICALS INC.</font></div><div style="padding-left:108pt;padding-right:108pt;text-align:center"><font><br></font></div><div style="padding-left:216pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">_____</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline"> Stephanie Smith</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">_________&#160;&#160;&#160;&#160;        </font></div><div style="padding-left:144pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160; By&#58;  &#160;&#160;&#160;&#160;Stephanie Smith, MBA, HRM</font></div><div style="padding-left:216pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">HR Manager</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Accepted as to all terms and conditions.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> as of the 9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> day of March 2023&#58;</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">______</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; A.J. Kazimi</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">_______________</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A.J. Kazimi </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.14
<SEQUENCE>6
<FILENAME>chrisbittermanemploymentag.htm
<DESCRIPTION>EX-10.14
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ia326ba55958e4e0782f7ded7cc1db8ee_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">March 9, 2023</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Chris Bitterman </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6440 Halcyon Garden Drive</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Alpharetta, GA 37090</font></div><div><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Re&#58;&#160;&#160;&#160;&#160;Employment of Chris Bitterman, Vice President of Sales and Marketing as by Cumberland Pharmaceuticals Inc.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Dear Chris, </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Effective January 1, 2023, this letter agreement (the &#8220;Agreement&#8221;) will evidence the terms and conditions under which you will be employed by Cumberland Pharmaceuticals Inc. (the &#8220;Company&#8221;) In consideration of your appointment as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Vice President of Sales and Marketing </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Company, and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties agree as follows&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Compensation.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  The Company agrees to compensate you as follows&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;The Company agrees to pay you on a salary basis for services performed based on an annual rate of two hundred fifty-eight thousand five hundred ($258,500.00) payable in arrears in equal monthly installments on the 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> day of each calendar month of 2023.  For each year, thereafter, you will be paid on a salary basis for services performed based on an annual rate determined by the Company in its sole discretion&#59; provided, however, that any obligation to make payments under this Section 1(a) will cease upon termination of your employment for any reason.  Notwithstanding the foregoing, nothing in this Section 1(a) alters or is intended to alter the at-will nature of your employment as described in Section 3 of this Agreement.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;You will be eligible to participate in any Company-wide employee benefits as approved by the Board of Directors.  The terms of your eligibility and participation will be governed by the provisions of the employee benefit plans, as such plans may be amended from time to time in the discretion of the Company's Board of Directors.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;You may be eligible for any Company bonus program, based upon performance in meeting your individual objectives and the Company&#8217;s overall performance, both as determined and approved by the Board of Directors of the Company.  Any such bonus will be discretionary and will be subject to the terms of the applicable bonus program, the terms of which program may be modified from year to year in the sole discretion of the Company&#8217;s Board of Directors.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-right:-4.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;You will receive a grant of Cumberland Pharmaceuticals common stock, pursuant to a stock options agreement (SOA).  Such shares will be subject to the SOA and the terms set forth in the incentive compensation plan under which they are awarded.  You may, at the Company&#8217;s sole discretion, receive additional awards of Company equity, which will be subject to their designated agreements and the incentive compensation plans under which they are awarded.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)&#160;&#160;&#160;&#160;Except as set forth in Section 2, the Company shall not be liable to you for any expense incurred by you unless you receive the Company's prior written consent to reimburse you for such expense.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:4.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Additional Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. During the term hereof, you shall be entitled to receive prompt reimbursement for all reasonable and documented expenses incurred in the performance of services in accordance with the expense reimbursement policy of the Company.  Such reimbursement policy shall require adequate documentation by you of the expenses and payment by the Company of such amounts shall be made within a reasonable period after the close of the year in which the expenses were incurred.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Employment at Will</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.   This Agreement is not intended to and shall not be understood in any manner as affecting or modifying the at-will status of your employment with the Company.  As an at-will employee either you or the Company may terminate the employment relationship at any time with or without cause or notice.  The obligations of Sections 4, 5, 6, 7, 8, 10, 11 and 12 herein shall survive the termination of the employment relationship or of this Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Confidentiality</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  All knowledge and information, not already available to the public, which you acquire, have acquired, or will acquire in the course of your employment with the Company with respect to the Company&#8217;s business, work methods, or pending regulatory matters, or other Company matters that are treated by the Company as confidential, shall be regarded by you as trade secrets, whether or not they are classifiable legally as trade secrets, and shall be treated by you as strictly confidential.  Such knowledge and information shall not either directly or indirectly be used, disclosed, or made accessible to anyone by you for any purpose, except in the ordinary course of the Company&#8217;s business when you are authorized to use or disclose such information.  No disclosures of such confidential information shall be made outside of those you are authorized to make in the regular and ordinary course of your duties unless and until you receive prior written permission of the Board of Directors of the Company to make such disclosure.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 5.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Discoveries and Improvements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  During the time that you are employed by the Company, all confidential information, trade secrets, or proprietary information and all other discoveries, inventions, software programs, processes, methods and improvements that are conceived, developed, or otherwise made by you , alone or with others, that relate in any way to the Company&#8217;s present or planned business or products (collectively the &#8220;Developments&#8221;), whether or not patentable or subject to copyright protection and whether or not reduced to tangible form or reduced to practice, shall be the sole property of the Company.  You agree to disclose all Developments promptly, fully and in writing to the Company.  You agree to keep and maintain adequate and current dated and witnessed written records of all such Developments, in the form of notes, sketches, drawings, or reports, which records shall be promptly submitted to the Company and shall be always and remain the property of the Company.  You agree to assign, and hereby do assign, to, the Company all your right, title, and interest throughout the world in and to all Developments.  You agree that all Developments shall constitute &#8220;Works for Hire&#8221; (as such are defined under the U.S. Copyright Laws) and hereby assign to the Company all copyrights, patents, and other proprietary rights you may have in any Developments without any obligation on the part of the Company to pay royalties or any other consideration to you for such Developments.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 6.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Publication</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  All documents and other writings produced by you during the period of your employment, which relate to work you are doing or have done for the Company or to the business of the Company or its affiliates, shall belong to the Company.  You will not publish outside of the Company any such writing without the prior written consent of the Board of Directors of the Company.  You will, without further compensation, execute at any time (whether or not you are still employed by the Company) all documents requested of you relating to the protection of such rights, including the assignment of such rights to the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Litigation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You shall notify the Company within three business days if no longer employed and immediately if still employed by the Company if you are contacted by any person </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">relating to any claim or litigation against the Company.  You shall not communicate in any manner with any person related to any claim or litigation against the Company without the prior consent of the Board of Directors of the Company unless compelled to do so by law.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Competition</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.   For so long as you are employed by the Company or any Affiliate (as defined below) and for a period of one year after you cease to be employed by the Company or any Affiliate, you shall not, directly or indirectly, engage in any work or other activity--whether as owner, stockholder, partner, officer, consultant, or otherwise--involving a trademark, product, or process that, in the opinion of the Company&#8217;s President, is  similar to a trademark, product or process on which you worked for the Company (or any Affiliate) or obtained knowledge about while working for the Company at any time during the period of employment, if such work or other activity is then, or reasonably expected to become, competitive with that of the Company (or any Affiliate).  The restriction in the preceding sentence shall not apply if you have disclosed to the Company in writing all the known facts relating to such work or activity and have received a release in writing from the Board of Directors of the Company allowing you to engage in such work or activity. The Company&#8217;s President shall have sole discretion to determine whether your work or activity for another employer involves trademarks, products, or processes that are similar to trademarks, products, or processes that you worked on for the Company. Ownership by you of five percent (5%) or less of the outstanding shares of stock of any company either (i) listed on a national securities exchange, or (ii) having at least one hundred (100) stockholders shall not make you a &#8220;stockholder&#8221; within the meaning of that term as used in this paragraph.  For one year after you cease to work for the Company, you will not engage in any work or activity that will cause you to inevitably disclose to anyone not employed by the Company (or an Affiliate) any trade secret or confidential information that belongs to the Company or one of its Affiliates.   Nothing in this paragraph shall limit the rights or remedies of the Company arising, directly or indirectly, from such competitive employment, including, without limitation, claims based upon breach of fiduciary duty, misappropriation, or theft of confidential information.  The term &#8220;Affiliate&#8221; shall mean the Company and any entity controlling, controlled by, or under common control with the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Conflicting Contracts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You represent and warrant that you are not now under any obligation resulting from any contract or arrangement to any person, firm, or corporation, which is inconsistent or in conflict with this Agreement.  Likewise, you represent and warrant that you are not now under any obligation resulting from any contract or arrangement to any person, firm, or corporation which would prevent, limit, or impair in any way the performance by you of your obligations to the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Solicitation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  For a period of one year after you cease to be employed by the Company (or a Company affiliate)&#58; </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;You agree not to solicit, directly or indirectly, business related to the development or sales of pharmaceutical products from any entity, organization, or person which is contracted with the Company, which has been doing business with the Company or from which the Company was soliciting at the time of your termination, or a firm which you knew or had reason to know that the Company was going to solicit business at the time you ceased to be employed by the Company.  The restriction set forth in the preceding sentence shall not apply if you have disclosed to the Company in writing all the known facts relating to such solicitation and have received a release in writing from the Board of Directors of the Company to engage in such solicitation.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;You agree not to solicit, recruit, hire, or assist in the hiring of any employee of the Company to work for you or another person, firm, corporation, or business in competition with, or reasonably likely to become in competition with, the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Return of Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Upon termination of your employment for any reason, you shall immediately return to the Company all documents and things belonging to the Company.  This includes, but is not limited to, trade secrets, confidential information, knowledge, data or know-how, and software containing such information, whether or not the documents are marked &#8220;Confidential.&#8221;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Remedies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You acknowledge that in the event of breach of this Agreement by you, actual damages to the Company will be impossible to calculate, the Company&#8217;s remedies at law will be inadequate, and the Company will suffer irreparable harm.  Therefore, you agree that any of the covenants contained in this Agreement may be specifically enforced through injunctive relief, but such right to injunctive relief shall not preclude the Company from other remedies which may be available to it.  You further agree that should you fail to keep any of the promises made by you in this Agreement, or any way violate this Agreement, the Company shall be entitled to recover all monies the Company is required to spend, including attorneys&#8217; fees, to enforce the provisions of this Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Best Efforts and Conflicts of Interest</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58;  You are hired with the understanding that Cumberland is your sole employer, and you will provide a full-time work effort. You agree to devote your entire professional and business-related time and best efforts to the services required of you by the express and implicit terms of this Agreement, to the reasonable satisfaction of Cumberland in its sole and complete discretion.  Engaging in activities outside of work that create a conflict of interest or detract from your ability to perform your assigned responsibilities or meet your defined goals and objectives with Cumberland, is a problem and may lead to disciplinary action up to and including termination of employment.  If you believe that you are potentially involved in a situation that could create a conflict of interest and affect your ability to adequately perform your job with&#160;Cumberland, you should inform your direct supervisor and Cumberland&#8217;s Human Resources Department immediately.</font></div><div id="ia326ba55958e4e0782f7ded7cc1db8ee_4"></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 14.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Debarment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You represent and warrant that you have not been debarred and will notify the Company immediately if you are debarred, pursuant to subsection 306(a) or 306(b) of the Federal Food, Drug, and Cosmetic Act.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 15.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Any notice required or permitted to be given under this Agreement shall be sufficient if in writing and if sent by registered or certified mail to your residence or to the Company&#8217;s principal office in the case of the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 16.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The waiver by either party of any provision of this Agreement shall not operate or be construed as a waiver of any subsequent breach.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 17.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Entire Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement contains the entire agreement of the parties and may not be changed orally, but only by an agreement in writing signed by the party against whom enforcement of any waiver, change, modification, extension, or discharge is sought.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 18.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Governance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement shall be governed by the laws of the State of Tennessee.  Any dispute arising out of this Agreement shall be resolved, at the Company&#8217;s sole option, by courts sitting in Nashville, Tennessee, and you waive any objection to such venue.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 19.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Enforceability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If any provision of this Agreement shall be held by a court to be unenforceable, such provision will be enforced to the maximum extent permissible, and the remaining portions of this Agreement shall remain in full force and effect.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">20.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Survival</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding any termination of your employment, this Agreement shall survive and remain in effect in accordance with its terms.</font></div><div style="padding-left:3pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:3pt;text-align:justify"><font><br></font></div><div style="padding-left:3pt;text-align:justify"><font><br></font></div><div style="padding-left:1.5pt;padding-right:1.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">#   #   #   #</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This letter agreement may be signed in one or more counterparts, each of which shall be an original and all of which will constitute one and the same instrument.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:216pt;text-align:justify"><font><br></font></div><div style="padding-left:216pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Sincerely yours,</font></div><div style="padding-left:216pt;text-align:justify"><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> CUMBERLAND PHARMACEUTICALS INC.</font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">_______________________________________&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; By&#58;  &#160;&#160;&#160;&#160;A.J. Kazimi</font></div><div style="padding-left:252pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Chief Executive Officer</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Accepted as to all terms and conditions.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as of the 9th of March 2023&#58;</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">_________</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Chris Bitterman</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">_____________</font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Chris Bitterman     </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>image_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_0.jpg
MB5!.1PT*&@H    -24A$4@  !G(   %W" (    >L$)N  "  $E$051X7NS=
M"5Q55YXO^GWO^WQNO_OI3[_J[O?Z];VWNKHK7?6I[GZWATJE*DFE*HF55,4A
ME4DSF<3,B<:H<4 $$51DD$%F05 0!!%0!%3 651$Q1E%!2<T<< Y1HE$Q+=D
MMZ=.UH+-6OOLO?8Z^_R^G__'3P*LL_][G;777OM_]CE'NP<           ""
M-/H'            T!^4U0           (2AK 8          " ,934
M      !A**L!           (0UD-          ! &,IJ            PE!6
M P          $(:R&@          @#"4U0           (2AK 8
M " ,934           !A**L!           (0UD-          ! &,IJ
M        PE!6 UIW=_>,F*IQDXOH7P          P ,HJP&MJ^ONIV/S1X[+
MIW\!           /H*P&M,[;=WXQ*.*S"07T+P          X &4U8#6WG[C
MSQ\=\_G$0OH7          #P ,IJ0*NHW/=?'OX$934           ,HJP%M
M\K0R[>>?C$%9#0        "@;RBK >VW+T3]EX<_'1.$;P(%         .@3
MRFKP/0</GOW;WTSXKP^/1%D-         ,  RFKP/=.CJ_[LD<_^#Y35
M       ,H:P&?W+K5N?@UQ+^VR]&H:P&         & ,937XDZJ5^__ZU^/^
MSU^.1ED-         , 8RFKP)Q^/R?MOOQCUWW^%LAH         0#]05H/_
MM&??Z7]^=NJ?_VHTRFH          /U"60WNZ^[NCIA5^6>_'/T7CX[!FT !
M         /J%LAK<MZWA^#_^;LH/'AV#LAH           ^4U>#^K6IC)A7]
M]U^._JO'QZ*L!@        #  V4UN+=TV>Z_>'3,7_]ZW%\]/NXO'OT<934
M        @'ZAK!;HVB_<>'A0Q%\]/O9OGQC_E_?O5D-9#0        "@?RBK
M!;3.VW<^'I/WYX]^_L/?3OR;7W^!LAH          ">4U0):Y.R5?_;(9S]Z
M<N+__,T$E-4          /BAK!:@NKN[8^)6_>7C8W_T5-"/GYJ$LAH
M    @!"4U0)48O+J_^NQ,3]^.NBG X)_]"3*:@          8E!6"S@W;MR>
M/JOBKQ\?]Y,!P?_T3,A/!DQ&60T         0!3*:H'ER.'SPS_*_,%C8_[E
MF9!_^T/8SWX7C+(:         ( )**L%D/D+-C_U8M0/GYSXBX'3'AD8_K]_
M'XJR&@        " .2BK!80M6X^]\7[&__SMQ'_[0]@3ST]_='#$?SP7AK(:
M         (!I**NYW)DS5\=,*OK)[Z;\TS,AOWTA<L"+LYYX?OHO!X>CK 8
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M934SKE_OR%^X]=,QN4->C1L[*7])R=;3;5^UM[>?:ONJN?D$B::F8RBK 0
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M-935          "LX[:RVJJ:IN=>B7UI^)SL^>N6E&Q=5+BEJ!AE-935
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M5D-9#0        ! #K\LJW5W=P=/+?G)[X(GAA9E9*Z9DU*=G%J-LAK*:@
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MK_=18_<KUC:6U0H*M_UX0/ S+\<.?G"WVLMO)P]Y+?Z'OYWXP6<+;MRX33<
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M3;W*&O^4I0?=/N )W:I&_I@<[^J': 5!VJ@66G_2C1UE;L8@AR?G$2IMZC/
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MV:.XN'C>O'F1D9&)B8GD5Y<O7Z:W!!#8OOGFFYDS9\;&QN[=NY?^'0
M  !81%Y9[=Z#&]96KUZ]>_=N$V6UY<N7+UNVK+R\G/Q;7%R<FYL;%Q<7%165
MEY>W?__^[[[[CMX>0* BQ\[$B1/)H43_ @         L(K6L1E165F9G9^L?
MKV:NK+9TZ=+2TM*RLK*2DI+BXN*%"Q<F)R=/GSY]]NS9Y"\O7+AP^_9M>JL
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M4UF-/'A65E9F9N;<'NGIZ<G)R7%Q<;-FS8J(B(B.CDY+2R,/M6?/'MS"!@
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M3",@$$3HBX!1:?+?I"[YI_>NG)RAJLZN<[Z?M9<+D\JIVKMVU=[UJSKG (@
M(8[5A+U[]V9D9&S>O'G[]NWZQ&H)"0EQ<7$3ZAGAVMBQ8\?4&U5/_%S\N5B1
MV*I-FS8=.'#@Q(D3ER]?KJVME6L(      " L!/Z6.W.G3N+%BV:/7NV\?%J
M&L9J,3$Q:JPVNI[X7^,?45%1$R=.%"\HUB4V1FRJJ,NA0X=.GSY]_?IU44>Y
MV@       '"ST,=JPHT;-W)R<LK+R]T8JS5FO%VT@7@%\9KIZ>FB=K-GSQ:;
MO7;MVGW[]AT^?/CRY<M??_VUW!        !P"2UB->'X\>,I*2EKUZZMKJYV
M=:QF$ N/4XRM)UXP-C96K$6L3JPW.SM;;/FB18NV;MVZ<^?.HT>/GCY]^MJU
M:]_7NU/OKW_]J]Q>        ""E=8C6ANKHZ)26EJJIJ\^;-81:KB3^/:61\
M/>/%Q3^,'QK+&/]K_%9L@-A@L?&B7JM6K1*-()KEX,&#!PX<^/333R]=NO15
MO>O7K]^\[^NOOZZMK?W^^^^_J_?MM]_R_E,        [:!2K"0L6+)@Q8X;Q
M/M (B=4,L??%U8N_S_AAPV+&ER<(X^J??3/6)18P*B6(2I64E#0TSJ)%BT2[
M[=BQ8Z=BV[9MQXX=.]NT:]>NR;L'        ]^D5J]V\>7/&C!F%A875U=7$
M:H:$^R;6,[;0D'Q?XY\;&Y]83_Q<_-=XS<8:,CMU2PQB@T4+R[L'
M]^D5JPDU-349&1D+%R[<O'DSL5KC6*TA*5/SM:3[$9NH0DH]49TI]QEU;"PU
M-36M$=$4F?=EU1.OL&+%"GG?        X#[M8C7ATT\_34I*JJBHV+AQ([&:
MO[&:P4C6#$:X-K61OPW9_B9E2Z\G7HI8#0      P L=8[6[=^_NW+ESTJ1)
MRY<OKZJJ(E8C5@,      -"-CK%:77VRMG[]^BE3IJQ8L6+=NG7$:L1J
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M/7OV)"8FSIHURWA@C5B-6"V2_?G,U:<[3?UMVXGM>V3^^(FH\B7[Y"4
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MM)=ZYW3LF=6A1^9SG5-_^E3TF=-7Y44! (@,556?BI*6M3XN>;E4C%_)?P
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MYX"9KP^?-VAX8?\A^>:Q6M\93[\TM>4+*>?.7Y-?16/6#DOBQ*T^<&[3A7H
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M%GN+U?KE=ND[X[=M$OL/+I!?47MV#$OJO$>3*TEIJ^R;^SJV(ILT&Q;4F3W
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M%7[':J^]W;G/C!\^-NK=C6X]E5LX+'VP^XSZ@0Z>H*,*"TD;9M_LP;$562N
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MYA4//E83#27J*"KNBMN#ZL'>U!Q4;1D?\R-U:N[EX\-\WQX=7#7[P+@ OG-
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MG+K_0 1][R<      &&&6 TFB-5LBM5FS*Q*RUK=KFM:QQY9APY?D-L=
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M^\0V_^F%Y)BXQ1<N_$5N00      $.Z(U6""6*VI6$V4/7N.9N>NZ] ]H\?
M66O7'I+;#@      1 9B-9@@5E-CM1T[/MFSYVCERCVB%J*^63E5UZ_?EAL.
M      !$#&(UF"!6:QRK?;COF/COMFV'XY(6_ZIU_)NC2T^>J)&;#
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ML# VL3QA4L7X^++71Q3T')CW_,M3'VF7V+%GUJ"WBF?/J5ZYZL#1(Y?D#04
M      @18C68<")6>ZM@\,AYPT87CQI7.G1T4:]79[;KEO:KY^/^N=7X3KVR
MAX]]9\'"7;MVG3IUZLIM'DP#      #Z(5:#"3MBM5X#\_J\/JO_D/R!0_-?
M'3KWM6%SN_3-?KK3Y']Y=OR#3T>_U#LG:<K*Y2OVGSIUY>J7-_DJ3P
MH#EB-9BP-E;KUN]>IB9*SX&Y7?O-:--YVL/M$A]J-;YUE[2D*2O75WUR[OPU
M'DD#      #N0JP&$Y;$:B^^DMFE3W:7?CDO]YXN_K=EAZ1?/A_[>*?)@]XL
M$J]_[OPU>:T       #N0:P&$\'':IU>R1+E^<[WOG;@%\_%MNV6/BJFK&+)
M/K[!$P      A =B-9@()E9KUS6M;=>TEAV3?_Y,],-M)PZ/6K"P;/>%"W^1
MUP$      .!FQ&HP$5BL]F2GR<^]//7AMHEBL8X]LC*F;]B[YXS\T@
M &&!6 TF HC5'GLA^=>MXW[XV,C.O6<LK]S/1Z<!     (#P1JP&$[[':O_6
M)J%%NXF_;ATO?OMPVXGE%7N_NGI3?CD      ("P0ZP&$[[$:O_R[/A?MX[_
MU?-Q/WDBZF=/14],J;QQHU9^(0      @#!%K 83S<9J/Z^/U1YZ.OI'?QK5
M]_7\_0<_EU\"       @K!&KP83W6.W!I^\]K2;^_8OG8_/F5,M_#
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M^:<       "XCU@-        \!NQ&@       . W8C4       # ;\1J
M    @-^(U0        "_$:L!        ?B-6 P       /Q&K 8       #X
MC5@-        \!NQ&@       . W8C4       # ;\1J        @-^(U0
M      "_$:L!        ?B-6 P       /Q&K 8       #X[?\#24]-*U^W
..27$     245.1*Y"8((!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.12
<SEQUENCE>8
<FILENAME>jameshermanemploymentagree.htm
<DESCRIPTION>EX-10.12
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i1a8d03c550a843f08f09724887d9c8b7_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">March 9, 2023</font></div><div style="text-align:justify"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">James &#8220;Jim&#8221; Herman</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">430 Brentwood Oaks Dr</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Nashville, TN 37221</font></div><div><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Re&#58;&#160;&#160;&#160;&#160;Employment of Jim Herman Executive Vice President National Accounts &#38; Chief Compliance Officer as by Cumberland Pharmaceuticals Inc.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Dear Jim, </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Effective January 1, 2023, this letter agreement (the &#8220;Agreement&#8221;) will evidence the terms and conditions under which you will be employed by Cumberland Pharmaceuticals Inc. (the &#8220;Company&#8221;) In consideration of your appointment as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Executive Vice President National Accounts &#38; Chief Compliance Officer </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Company, and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties agree as follows&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Compensation.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  The Company agrees to compensate you as follows&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;The Company agrees to pay you on a salary basis for services performed based on an annual rate of three hundred ten thousand ($310,000) payable in arrears in equal monthly installments on the 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> day of each calendar month of 2023.  For each year, thereafter, you will be paid on a salary basis for services performed based on an annual rate determined by the Company in its sole discretion&#59; provided, however, that any obligation to make payments under this Section 1(a) will cease upon termination of your employment for any reason.  Notwithstanding the foregoing, nothing in this Section 1(a) alters or is intended to alter the at-will nature of your employment as described in Section 3 of this Agreement.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;You will be eligible to participate in any Company-wide employee benefits as approved by the Board of Directors.  The terms of your eligibility and participation will be governed by the provisions of the employee benefit plans, as such plans may be amended from time to time in the discretion of the Company's Board of Directors.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;You may be eligible for any Company bonus program, based upon performance in meeting your individual objectives and the Company&#8217;s overall performance, both as determined and approved by the Board of Directors of the Company.  Any such bonus will be discretionary and will be subject to the terms of the applicable bonus program, the terms of which program may be modified from year to year in the sole discretion of the Company&#8217;s Board of Directors.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-right:-4.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;You will receive a grant of Cumberland Pharmaceuticals common stock, pursuant to a stock options agreement (SOA).  Such shares will be subject to the SOA and the terms set forth in the incentive compensation plan under which they are awarded.  You may, at the Company&#8217;s sole discretion, receive additional awards of Company equity, which will be subject to their designated agreements and the incentive compensation plans under which they are awarded.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)&#160;&#160;&#160;&#160;Except as set forth in Section 2, the Company shall not be liable to you for any expense incurred by you unless you receive the Company's prior written consent to reimburse you for such expense.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:4.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Additional Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. During the term hereof, you shall be entitled to receive prompt reimbursement for all reasonable and documented expenses incurred in the performance of services in accordance with the expense reimbursement policy of the Company.  Such reimbursement policy shall require adequate documentation by you of the expenses and payment by the Company of such amounts shall be made within a reasonable period after the close of the year in which the expenses were incurred.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Employment at Will</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.   This Agreement is not intended to and shall not be understood in any manner as affecting or modifying the at-will status of your employment with the Company.  As an at-will employee either you or the Company may terminate the employment relationship at any time with or without cause or notice.  The obligations of Sections 4, 5, 6, 7, 8, 10, 11 and 12 herein shall survive the termination of the employment relationship or of this Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Confidentiality</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  All knowledge and information, not already available to the public, which you acquire, have acquired, or will acquire in the course of your employment with the Company with respect to the Company&#8217;s business, work methods, or pending regulatory matters, or other Company matters that are treated by the Company as confidential, shall be regarded by you as trade secrets, whether or not they are classifiable legally as trade secrets, and shall be treated by you as strictly confidential.  Such knowledge and information shall not either directly or indirectly be used, disclosed, or made accessible to anyone by you for any purpose, except in the ordinary course of the Company&#8217;s business when you are authorized to use or disclose such information.  No disclosures of such confidential information shall be made outside of those you are authorized to make in the regular and ordinary course of your duties unless and until you receive prior written permission of the Board of Directors of the Company to make such disclosure.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 5.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Discoveries and Improvements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  During the time that you are employed by the Company, all confidential information, trade secrets, or proprietary information and all other discoveries, inventions, software programs, processes, methods and improvements that are conceived, developed, or otherwise made by you , alone or with others, that relate in any way to the Company&#8217;s present or planned business or products (collectively the &#8220;Developments&#8221;), whether or not patentable or subject to copyright protection and whether or not reduced to tangible form or reduced to practice, shall be the sole property of the Company.  You agree to disclose all Developments promptly, fully and in writing to the Company.  You agree to keep and maintain adequate and current dated and witnessed written records of all such Developments, in the form of notes, sketches, drawings, or reports, which records shall be promptly submitted to the Company and shall be always and remain the property of the Company.  You agree to assign, and hereby do assign, to, the Company all your right, title, and interest throughout the world in and to all Developments.  You agree that all Developments shall constitute &#8220;Works for Hire&#8221; (as such are defined under the U.S. Copyright Laws) and hereby assign to the Company all copyrights, patents, and other proprietary rights you may have in any Developments without any obligation on the part of the Company to pay royalties or any other consideration to you for such Developments.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 6.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Publication</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  All documents and other writings produced by you during the period of your employment, which relate to work you are doing or have done for the Company or to the business of the Company or its affiliates, shall belong to the Company.  You will not publish outside of the Company any such writing without the prior written consent of the Board of Directors of the Company.  You will, without further compensation, execute at any time (whether or not you are still employed by the Company) all documents requested of you relating to the protection of such rights, including the assignment of such rights to the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Litigation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You shall notify the Company within three business days if no longer employed and immediately if still employed by the Company if you are contacted by any person </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">relating to any claim or litigation against the Company.  You shall not communicate in any manner with any person related to any claim or litigation against the Company without the prior consent of the Board of Directors of the Company unless compelled to do so by law.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Competition</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.   For so long as you are employed by the Company or any Affiliate (as defined below) and for a period of one year after you cease to be employed by the Company or any Affiliate, you shall not, directly or indirectly, engage in any work or other activity--whether as owner, stockholder, partner, officer, consultant, or otherwise--involving a trademark, product, or process that, in the opinion of the Company&#8217;s President, is  similar to a trademark, product or process on which you worked for the Company (or any Affiliate) or obtained knowledge about while working for the Company at any time during the period of employment, if such work or other activity is then, or reasonably expected to become, competitive with that of the Company (or any Affiliate).  The restriction in the preceding sentence shall not apply if you have disclosed to the Company in writing all the known facts relating to such work or activity and have received a release in writing from the Board of Directors of the Company allowing you to engage in such work or activity. The Company&#8217;s President shall have sole discretion to determine whether your work or activity for another employer involves trademarks, products, or processes that are similar to trademarks, products, or processes that you worked on for the Company. Ownership by you of five percent (5%) or less of the outstanding shares of stock of any company either (i) listed on a national securities exchange, or (ii) having at least one hundred (100) stockholders shall not make you a &#8220;stockholder&#8221; within the meaning of that term as used in this paragraph.  For one year after you cease to work for the Company, you will not engage in any work or activity that will cause you to inevitably disclose to anyone not employed by the Company (or an Affiliate) any trade secret or confidential information that belongs to the Company or one of its Affiliates.   Nothing in this paragraph shall limit the rights or remedies of the Company arising, directly or indirectly, from such competitive employment, including, without limitation, claims based upon breach of fiduciary duty, misappropriation, or theft of confidential information.  The term &#8220;Affiliate&#8221; shall mean the Company and any entity controlling, controlled by, or under common control with the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Conflicting Contracts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You represent and warrant that you are not now under any obligation resulting from any contract or arrangement to any person, firm, or corporation, which is inconsistent or in conflict with this Agreement.  Likewise, you represent and warrant that you are not now under any obligation resulting from any contract or arrangement to any person, firm, or corporation which would prevent, limit, or impair in any way the performance by you of your obligations to the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Solicitation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  For a period of one year after you cease to be employed by the Company (or a Company affiliate)&#58; </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;You agree not to solicit, directly or indirectly, business related to the development or sales of pharmaceutical products from any entity, organization, or person which is contracted with the Company, which has been doing business with the Company or from which the Company was soliciting at the time of your termination, or a firm which you knew or had reason to know that the Company was going to solicit business at the time you ceased to be employed by the Company.  The restriction set forth in the preceding sentence shall not apply if you have disclosed to the Company in writing all the known facts relating to such solicitation and have received a release in writing from the Board of Directors of the Company to engage in such solicitation.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;You agree not to solicit, recruit, hire, or assist in the hiring of any employee of the Company to work for you or another person, firm, corporation, or business in competition with, or reasonably likely to become in competition with, the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Return of Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Upon termination of your employment for any reason, you shall immediately return to the Company all documents and things belonging to the Company.  This includes, but is not limited to, trade secrets, confidential information, knowledge, data or know-how, and software containing such information, whether or not the documents are marked &#8220;Confidential.&#8221;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Remedies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You acknowledge that in the event of breach of this Agreement by you, actual damages to the Company will be impossible to calculate, the Company&#8217;s remedies at law will be inadequate, and the Company will suffer irreparable harm.  Therefore, you agree that any of the covenants contained in this Agreement may be specifically enforced through injunctive relief, but such right to injunctive relief shall not preclude the Company from other remedies which may be available to it.  You further agree that should you fail to keep any of the promises made by you in this Agreement, or any way violate this Agreement, the Company shall be entitled to recover all monies the Company is required to spend, including attorneys&#8217; fees, to enforce the provisions of this Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Best Efforts and Conflicts of Interest</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58;  You are hired with the understanding that Cumberland is your sole employer, and you will provide a full-time work effort. You agree to devote your entire professional and business-related time and best efforts to the services required of you by the express and implicit terms of this Agreement, to the reasonable satisfaction of Cumberland in its sole and complete discretion.  Engaging in activities outside of work that create a conflict of interest or detract from your ability to perform your assigned responsibilities or meet your defined goals and objectives with Cumberland, is a problem and may lead to disciplinary action up to and including termination of employment.  If you believe that you are potentially involved in a situation that could create a conflict of interest and affect your ability to adequately perform your job with&#160;Cumberland, you should inform your direct supervisor and Cumberland&#8217;s Human Resources Department immediately.</font></div><div id="i1a8d03c550a843f08f09724887d9c8b7_4"></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 14.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Debarment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You represent and warrant that you have not been debarred and will notify the Company immediately if you are debarred, pursuant to subsection 306(a) or 306(b) of the Federal Food, Drug, and Cosmetic Act.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 15.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Any notice required or permitted to be given under this Agreement shall be sufficient if in writing and if sent by registered or certified mail to your residence or to the Company&#8217;s principal office in the case of the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 16.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The waiver by either party of any provision of this Agreement shall not operate or be construed as a waiver of any subsequent breach.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 17.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Entire Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement contains the entire agreement of the parties and may not be changed orally, but only by an agreement in writing signed by the party against whom enforcement of any waiver, change, modification, extension, or discharge is sought.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 18.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Governance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement shall be governed by the laws of the State of Tennessee.  Any dispute arising out of this Agreement shall be resolved, at the Company&#8217;s sole option, by courts sitting in Nashville, Tennessee, and you waive any objection to such venue.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 19.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Enforceability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If any provision of this Agreement shall be held by a court to be unenforceable, such provision will be enforced to the maximum extent permissible, and the remaining portions of this Agreement shall remain in full force and effect.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">20.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Survival</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding any termination of your employment, this Agreement shall survive and remain in effect in accordance with its terms.</font></div><div style="padding-left:3pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:3pt;text-align:justify"><font><br></font></div><div style="padding-left:3pt;text-align:justify"><font><br></font></div><div style="padding-left:1.5pt;padding-right:1.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">#   #   #   #</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This letter agreement may be signed in one or more counterparts, each of which shall be an original and all of which will constitute one and the same instrument.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:216pt;text-align:justify"><font><br></font></div><div style="padding-left:216pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Sincerely yours,</font></div><div style="padding-left:216pt;text-align:justify"><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> CUMBERLAND PHARMACEUTICALS INC.</font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">_______________________________________&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; By&#58;  &#160;&#160;&#160;&#160;A.J. Kazimi</font></div><div style="padding-left:252pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Chief Executive Officer</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Accepted as to all terms and conditions.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as of the 9th of March 2023&#58;</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">____________</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Jim Herman</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">_____________</font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">James &#8220;Jim&#8221; Herman    </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.15
<SEQUENCE>9
<FILENAME>johnhammemploymentagreemen.htm
<DESCRIPTION>EX-10.15
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i84bae12c0a43449a9560fe6bce00e9bd_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">March 9, 2023</font></div><div style="text-align:justify"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">John Hamm</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1659 Kirkwood Place</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Brentwood, TN 37216</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Re&#58;&#160;&#160;&#160;&#160;Employment of John Hamm Chief Financial Officer as by Cumberland Pharmaceuticals Inc.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Dear John, </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Effective January 1, 2023, this letter agreement (the &#8220;Agreement&#8221;) will evidence the terms and conditions under which you will be employed by Cumberland Pharmaceuticals Inc. (the &#8220;Company&#8221;) In consideration of your appointment as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Chief Financial Officer </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Company, and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties agree as follows&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Compensation.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  The Company agrees to compensate you as follows&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;The Company agrees to pay you on a salary basis for services performed based on an annual rate of two hundred and twenty-eight thousand ($228,000.00) payable in arrears in equal monthly installments on the 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> day of each calendar month of 2023.  For each year, thereafter, you will be paid on a salary basis for services performed based on an annual rate determined by the Company in its sole discretion&#59; provided, however, that any obligation to make payments under this Section 1(a) will cease upon termination of your employment for any reason.  Notwithstanding the foregoing, nothing in this Section 1(a) alters or is intended to alter the at-will nature of your employment as described in Section 3 of this Agreement.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;You will be eligible to participate in any Company-wide employee benefits as approved by the Board of Directors.  The terms of your eligibility and participation will be governed by the provisions of the employee benefit plans, as such plans may be amended from time to time in the discretion of the Company's Board of Directors.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;You may be eligible for any Company bonus program, based upon performance in meeting your individual objectives and the Company&#8217;s overall performance, both as determined and approved by the Board of Directors of the Company.  Any such bonus will be discretionary and will be subject to the terms of the applicable bonus program, the terms of which program may be modified from year to year in the sole discretion of the Company&#8217;s Board of Directors.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-right:-4.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;You will receive a grant of Cumberland Pharmaceuticals common stock, pursuant to a stock options agreement (SOA).  Such shares will be subject to the SOA and the terms set forth in the incentive compensation plan under which they are awarded.  You may, at the Company&#8217;s sole discretion, receive additional awards of Company equity, which will be subject to their designated agreements and the incentive compensation plans under which they are awarded.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)&#160;&#160;&#160;&#160;Except as set forth in Section 2, the Company shall not be liable to you for any expense incurred by you unless you receive the Company's prior written consent to reimburse you for such expense.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:4.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Additional Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. During the term hereof, you shall be entitled to receive prompt reimbursement for all reasonable and documented expenses incurred in the performance of services in accordance with the expense reimbursement policy of the Company.  Such reimbursement policy shall require adequate documentation by you of the expenses and payment by the Company of such amounts shall be made within a reasonable period after the close of the year in which the expenses were incurred.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Employment at Will</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.   This Agreement is not intended to and shall not be understood in any manner as affecting or modifying the at-will status of your employment with the Company.  As an at-will employee either you or the Company may terminate the employment relationship at any time with or without cause or notice.  The obligations of Sections 4, 5, 6, 7, 8, 10, 11 and 12 herein shall survive the termination of the employment relationship or of this Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Confidentiality</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  All knowledge and information, not already available to the public, which you acquire, have acquired, or will acquire in the course of your employment with the Company with respect to the Company&#8217;s business, work methods, or pending regulatory matters, or other Company matters that are treated by the Company as confidential, shall be regarded by you as trade secrets, whether or not they are classifiable legally as trade secrets, and shall be treated by you as strictly confidential.  Such knowledge and information shall not either directly or indirectly be used, disclosed, or made accessible to anyone by you for any purpose, except in the ordinary course of the Company&#8217;s business when you are authorized to use or disclose such information.  No disclosures of such confidential information shall be made outside of those you are authorized to make in the regular and ordinary course of your duties unless and until you receive prior written permission of the Board of Directors of the Company to make such disclosure.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 5.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Discoveries and Improvements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  During the time that you are employed by the Company, all confidential information, trade secrets, or proprietary information and all other discoveries, inventions, software programs, processes, methods and improvements that are conceived, developed, or otherwise made by you , alone or with others, that relate in any way to the Company&#8217;s present or planned business or products (collectively the &#8220;Developments&#8221;), whether or not patentable or subject to copyright protection and whether or not reduced to tangible form or reduced to practice, shall be the sole property of the Company.  You agree to disclose all Developments promptly, fully and in writing to the Company.  You agree to keep and maintain adequate and current dated and witnessed written records of all such Developments, in the form of notes, sketches, drawings, or reports, which records shall be promptly submitted to the Company and shall be always and remain the property of the Company.  You agree to assign, and hereby do assign, to, the Company all your right, title, and interest throughout the world in and to all Developments.  You agree that all Developments shall constitute &#8220;Works for Hire&#8221; (as such are defined under the U.S. Copyright Laws) and hereby assign to the Company all copyrights, patents, and other proprietary rights you may have in any Developments without any obligation on the part of the Company to pay royalties or any other consideration to you for such Developments.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 6.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Publication</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  All documents and other writings produced by you during the period of your employment, which relate to work you are doing or have done for the Company or to the business of the Company or its affiliates, shall belong to the Company.  You will not publish outside of the Company any such writing without the prior written consent of the Board of Directors of the Company.  You will, without further compensation, execute at any time (whether or not you are still employed by the Company) all documents requested of you relating to the protection of such rights, including the assignment of such rights to the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Litigation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You shall notify the Company within three business days if no longer employed and immediately if still employed by the Company if you are contacted by any person </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">relating to any claim or litigation against the Company.  You shall not communicate in any manner with any person related to any claim or litigation against the Company without the prior consent of the Board of Directors of the Company unless compelled to do so by law.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Competition</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.   For so long as you are employed by the Company or any Affiliate (as defined below) and for a period of one year after you cease to be employed by the Company or any Affiliate, you shall not, directly or indirectly, engage in any work or other activity--whether as owner, stockholder, partner, officer, consultant, or otherwise--involving a trademark, product, or process that, in the opinion of the Company&#8217;s President, is  similar to a trademark, product or process on which you worked for the Company (or any Affiliate) or obtained knowledge about while working for the Company at any time during the period of employment, if such work or other activity is then, or reasonably expected to become, competitive with that of the Company (or any Affiliate).  The restriction in the preceding sentence shall not apply if you have disclosed to the Company in writing all the known facts relating to such work or activity and have received a release in writing from the Board of Directors of the Company allowing you to engage in such work or activity. The Company&#8217;s President shall have sole discretion to determine whether your work or activity for another employer involves trademarks, products, or processes that are similar to trademarks, products, or processes that you worked on for the Company. Ownership by you of five percent (5%) or less of the outstanding shares of stock of any company either (i) listed on a national securities exchange, or (ii) having at least one hundred (100) stockholders shall not make you a &#8220;stockholder&#8221; within the meaning of that term as used in this paragraph.  For one year after you cease to work for the Company, you will not engage in any work or activity that will cause you to inevitably disclose to anyone not employed by the Company (or an Affiliate) any trade secret or confidential information that belongs to the Company or one of its Affiliates.   Nothing in this paragraph shall limit the rights or remedies of the Company arising, directly or indirectly, from such competitive employment, including, without limitation, claims based upon breach of fiduciary duty, misappropriation, or theft of confidential information.  The term &#8220;Affiliate&#8221; shall mean the Company and any entity controlling, controlled by, or under common control with the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Conflicting Contracts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You represent and warrant that you are not now under any obligation resulting from any contract or arrangement to any person, firm, or corporation, which is inconsistent or in conflict with this Agreement.  Likewise, you represent and warrant that you are not now under any obligation resulting from any contract or arrangement to any person, firm, or corporation which would prevent, limit, or impair in any way the performance by you of your obligations to the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Solicitation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  For a period of one year after you cease to be employed by the Company (or a Company affiliate)&#58; </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;You agree not to solicit, directly or indirectly, business related to the development or sales of pharmaceutical products from any entity, organization, or person which is contracted with the Company, which has been doing business with the Company or from which the Company was soliciting at the time of your termination, or a firm which you knew or had reason to know that the Company was going to solicit business at the time you ceased to be employed by the Company.  The restriction set forth in the preceding sentence shall not apply if you have disclosed to the Company in writing all the known facts relating to such solicitation and have received a release in writing from the Board of Directors of the Company to engage in such solicitation.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;You agree not to solicit, recruit, hire, or assist in the hiring of any employee of the Company to work for you or another person, firm, corporation, or business in competition with, or reasonably likely to become in competition with, the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Return of Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Upon termination of your employment for any reason, you shall immediately return to the Company all documents and things belonging to the Company.  This includes, but is not limited to, trade secrets, confidential information, knowledge, data or know-how, and software containing such information, whether or not the documents are marked &#8220;Confidential.&#8221;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Remedies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You acknowledge that in the event of breach of this Agreement by you, actual damages to the Company will be impossible to calculate, the Company&#8217;s remedies at law will be inadequate, and the Company will suffer irreparable harm.  Therefore, you agree that any of the covenants contained in this Agreement may be specifically enforced through injunctive relief, but such right to injunctive relief shall not preclude the Company from other remedies which may be available to it.  You further agree that should you fail to keep any of the promises made by you in this Agreement, or any way violate this Agreement, the Company shall be entitled to recover all monies the Company is required to spend, including attorneys&#8217; fees, to enforce the provisions of this Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Best Efforts and Conflicts of Interest</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58;  You are hired with the understanding that Cumberland is your sole employer, and you will provide a full-time work effort. You agree to devote your entire professional and business-related time and best efforts to the services required of you by the express and implicit terms of this Agreement, to the reasonable satisfaction of Cumberland in its sole and complete discretion.  Engaging in activities outside of work that create a conflict of interest or detract from your ability to perform your assigned responsibilities or meet your defined goals and objectives with Cumberland, is a problem and may lead to disciplinary action up to and including termination of employment.  If you believe that you are potentially involved in a situation that could create a conflict of interest and affect your ability to adequately perform your job with&#160;Cumberland, you should inform your direct supervisor and Cumberland&#8217;s Human Resources Department immediately.</font></div><div id="i84bae12c0a43449a9560fe6bce00e9bd_4"></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 14.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Debarment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You represent and warrant that you have not been debarred and will notify the Company immediately if you are debarred, pursuant to subsection 306(a) or 306(b) of the Federal Food, Drug, and Cosmetic Act.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 15.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Any notice required or permitted to be given under this Agreement shall be sufficient if in writing and if sent by registered or certified mail to your residence or to the Company&#8217;s principal office in the case of the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 16.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The waiver by either party of any provision of this Agreement shall not operate or be construed as a waiver of any subsequent breach.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 17.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Entire Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement contains the entire agreement of the parties and may not be changed orally, but only by an agreement in writing signed by the party against whom enforcement of any waiver, change, modification, extension, or discharge is sought.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 18.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Governance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement shall be governed by the laws of the State of Tennessee.  Any dispute arising out of this Agreement shall be resolved, at the Company&#8217;s sole option, by courts sitting in Nashville, Tennessee, and you waive any objection to such venue.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 19.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Enforceability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If any provision of this Agreement shall be held by a court to be unenforceable, such provision will be enforced to the maximum extent permissible, and the remaining portions of this Agreement shall remain in full force and effect.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">20.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Survival</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding any termination of your employment, this Agreement shall survive and remain in effect in accordance with its terms.</font></div><div style="padding-left:3pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:3pt;text-align:justify"><font><br></font></div><div style="padding-left:3pt;text-align:justify"><font><br></font></div><div style="padding-left:1.5pt;padding-right:1.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">#   #   #   #</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This letter agreement may be signed in one or more counterparts, each of which shall be an original and all of which will constitute one and the same instrument.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:216pt;text-align:justify"><font><br></font></div><div style="padding-left:216pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Sincerely yours,</font></div><div style="padding-left:216pt;text-align:justify"><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> CUMBERLAND PHARMACEUTICALS INC.</font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">_______________________________________&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; By&#58;  &#160;&#160;&#160;&#160;A.J. Kazimi</font></div><div style="padding-left:252pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Chief Executive Officer</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Accepted as to all terms and conditions.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as of the 9th of March 2023&#58;</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">____________</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; John Hamm</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">____________</font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">John Hamm, CFO</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.13
<SEQUENCE>10
<FILENAME>toddanthony-employmentagre.htm
<DESCRIPTION>EX-10.13
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i948cd6629d6e40e8bea0cae6137ef94c_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">March 9, 2023</font></div><div style="text-align:justify"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Todd Anthony</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">702 Meeting Street</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Franklin, TN 37064</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Re&#58;&#160;&#160;&#160;&#160;Employment of Todd Anthony Vice President of Organizational Development as by Cumberland Pharmaceuticals Inc.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Dear Todd, </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Effective January 1, 2023, this letter agreement (the &#8220;Agreement&#8221;) will evidence the terms and conditions under which you will be employed by Cumberland Pharmaceuticals Inc. (the &#8220;Company&#8221;) In consideration of your appointment as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Vice President of Organizational Development</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> the Company, and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties agree as follows&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Compensation.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  The Company agrees to compensate you as follows&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;The Company agrees to pay you on a salary basis for services performed based on an annual rate of two hundred fifty-two thousand five hundred ($272,500.00), payable in arrears in equal monthly installments on the 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> day of each calendar month of 2023.  For each year, thereafter, you will be paid on a salary basis for services performed based on an annual rate determined by the Company in its sole discretion&#59; provided, however, that any obligation to make payments under this Section 1(a) will cease upon termination of your employment for any reason.  Notwithstanding the foregoing, nothing in this Section 1(a) alters or is intended to alter the at-will nature of your employment as described in Section 3 of this Agreement.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;You will be eligible to participate in any Company-wide employee benefits as approved by the Board of Directors.  The terms of your eligibility and participation will be governed by the provisions of the employee benefit plans, as such plans may be amended from time to time in the discretion of the Company's Board of Directors.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;You may be eligible for any Company bonus program, based upon performance in meeting your individual objectives and the Company&#8217;s overall performance, both as determined and approved by the Board of Directors of the Company.  Any such bonus will be discretionary and will be subject to the terms of the applicable bonus program, the terms of which program may be modified from year to year in the sole discretion of the Company&#8217;s Board of Directors.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-right:-4.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;You will receive a grant of Cumberland Pharmaceuticals common stock, pursuant to a stock options agreement (SOA).  Such shares will be subject to the SOA and the terms set forth in the incentive compensation plan under which they are awarded.  You may, at the Company&#8217;s sole discretion, receive additional awards of Company equity, which will be subject to their designated agreements and the incentive compensation plans under which they are awarded.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)&#160;&#160;&#160;&#160;Except as set forth in Section 2, the Company shall not be liable to you for any expense incurred by you unless you receive the Company's prior written consent to reimburse you for such expense.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:4.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Additional Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. During the term hereof, you shall be entitled to receive prompt reimbursement for all reasonable and documented expenses incurred in the performance of services in accordance with the expense reimbursement policy of the Company.  Such reimbursement policy shall require adequate documentation by you of the expenses and payment by the Company of such amounts shall be made within a reasonable period after the close of the year in which the expenses were incurred.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Employment at Will</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.   This Agreement is not intended to and shall not be understood in any manner as affecting or modifying the at-will status of your employment with the Company.  As an at-will employee either you or the Company may terminate the employment relationship at any time with or without cause or notice.  The obligations of Sections 4, 5, 6, 7, 8, 10, 11 and 12 herein shall survive the termination of the employment relationship or of this Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Confidentiality</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  All knowledge and information, not already available to the public, which you acquire, have acquired, or will acquire in the course of your employment with the Company with respect to the Company&#8217;s business, work methods, or pending regulatory matters, or other Company matters that are treated by the Company as confidential, shall be regarded by you as trade secrets, whether or not they are classifiable legally as trade secrets, and shall be treated by you as strictly confidential.  Such knowledge and information shall not either directly or indirectly be used, disclosed, or made accessible to anyone by you for any purpose, except in the ordinary course of the Company&#8217;s business when you are authorized to use or disclose such information.  No disclosures of such confidential information shall be made outside of those you are authorized to make in the regular and ordinary course of your duties unless and until you receive prior written permission of the Board of Directors of the Company to make such disclosure.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 5.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Discoveries and Improvements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  During the time that you are employed by the Company, all confidential information, trade secrets, or proprietary information and all other discoveries, inventions, software programs, processes, methods and improvements that are conceived, developed, or otherwise made by you , alone or with others, that relate in any way to the Company&#8217;s present or planned business or products (collectively the &#8220;Developments&#8221;), whether or not patentable or subject to copyright protection and whether or not reduced to tangible form or reduced to practice, shall be the sole property of the Company.  You agree to disclose all Developments promptly, fully and in writing to the Company.  You agree to keep and maintain adequate and current dated and witnessed written records of all such Developments, in the form of notes, sketches, drawings, or reports, which records shall be promptly submitted to the Company and shall be always and remain the property of the Company.  You agree to assign, and hereby do assign, to, the Company all your right, title, and interest throughout the world in and to all Developments.  You agree that all Developments shall constitute &#8220;Works for Hire&#8221; (as such are defined under the U.S. Copyright Laws) and hereby assign to the Company all copyrights, patents, and other proprietary rights you may have in any Developments without any obligation on the part of the Company to pay royalties or any other consideration to you for such Developments.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 6.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Publication</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  All documents and other writings produced by you during the period of your employment, which relate to work you are doing or have done for the Company or to the business of the Company or its affiliates, shall belong to the Company.  You will not publish outside of the Company any such writing without the prior written consent of the Board of Directors of the Company.  You will, without further compensation, execute at any time (whether or not you are still employed by the Company) all documents requested of you relating to the protection of such rights, including the assignment of such rights to the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Litigation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You shall notify the Company within three business days if no longer employed and immediately if still employed by the Company if you are contacted by any person </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">relating to any claim or litigation against the Company.  You shall not communicate in any manner with any person related to any claim or litigation against the Company without the prior consent of the Board of Directors of the Company unless compelled to do so by law.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Competition</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.   For so long as you are employed by the Company or any Affiliate (as defined below) and for a period of one year after you cease to be employed by the Company or any Affiliate, you shall not, directly or indirectly, engage in any work or other activity--whether as owner, stockholder, partner, officer, consultant, or otherwise--involving a trademark, product, or process that, in the opinion of the Company&#8217;s President, is  similar to a trademark, product or process on which you worked for the Company (or any Affiliate) or obtained knowledge about while working for the Company at any time during the period of employment, if such work or other activity is then, or reasonably expected to become, competitive with that of the Company (or any Affiliate).  The restriction in the preceding sentence shall not apply if you have disclosed to the Company in writing all the known facts relating to such work or activity and have received a release in writing from the Board of Directors of the Company allowing you to engage in such work or activity. The Company&#8217;s President shall have sole discretion to determine whether your work or activity for another employer involves trademarks, products, or processes that are similar to trademarks, products, or processes that you worked on for the Company. Ownership by you of five percent (5%) or less of the outstanding shares of stock of any company either (i) listed on a national securities exchange, or (ii) having at least one hundred (100) stockholders shall not make you a &#8220;stockholder&#8221; within the meaning of that term as used in this paragraph.  For one year after you cease to work for the Company, you will not engage in any work or activity that will cause you to inevitably disclose to anyone not employed by the Company (or an Affiliate) any trade secret or confidential information that belongs to the Company or one of its Affiliates.   Nothing in this paragraph shall limit the rights or remedies of the Company arising, directly or indirectly, from such competitive employment, including, without limitation, claims based upon breach of fiduciary duty, misappropriation, or theft of confidential information.  The term &#8220;Affiliate&#8221; shall mean the Company and any entity controlling, controlled by, or under common control with the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Conflicting Contracts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You represent and warrant that you are not now under any obligation resulting from any contract or arrangement to any person, firm, or corporation, which is inconsistent or in conflict with this Agreement.  Likewise, you represent and warrant that you are not now under any obligation resulting from any contract or arrangement to any person, firm, or corporation which would prevent, limit, or impair in any way the performance by you of your obligations to the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Solicitation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  For a period of one year after you cease to be employed by the Company (or a Company affiliate)&#58; </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;You agree not to solicit, directly or indirectly, business related to the development or sales of pharmaceutical products from any entity, organization, or person which is contracted with the Company, which has been doing business with the Company or from which the Company was soliciting at the time of your termination, or a firm which you knew or had reason to know that the Company was going to solicit business at the time you ceased to be employed by the Company.  The restriction set forth in the preceding sentence shall not apply if you have disclosed to the Company in writing all the known facts relating to such solicitation and have received a release in writing from the Board of Directors of the Company to engage in such solicitation.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;You agree not to solicit, recruit, hire, or assist in the hiring of any employee of the Company to work for you or another person, firm, corporation, or business in competition with, or reasonably likely to become in competition with, the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Return of Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Upon termination of your employment for any reason, you shall immediately return to the Company all documents and things belonging to the Company.  This includes, but is not limited to, trade secrets, confidential information, knowledge, data or know-how, and software containing such information, whether or not the documents are marked &#8220;Confidential.&#8221;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Remedies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You acknowledge that in the event of breach of this Agreement by you, actual damages to the Company will be impossible to calculate, the Company&#8217;s remedies at law will be inadequate, and the Company will suffer irreparable harm.  Therefore, you agree that any of the covenants contained in this Agreement may be specifically enforced through injunctive relief, but such right to injunctive relief shall not preclude the Company from other remedies which may be available to it.  You further agree that should you fail to keep any of the promises made by you in this Agreement, or any way violate this Agreement, the Company shall be entitled to recover all monies the Company is required to spend, including attorneys&#8217; fees, to enforce the provisions of this Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Best Efforts and Conflicts of Interest</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58;  You are hired with the understanding that Cumberland is your sole employer, and you will provide a full-time work effort. You agree to devote your entire professional and business-related time and best efforts to the services required of you by the express and implicit terms of this Agreement, to the reasonable satisfaction of Cumberland in its sole and complete discretion.  Engaging in activities outside of work that create a conflict of interest or detract from your ability to perform your assigned responsibilities or meet your defined goals and objectives with Cumberland, is a problem and may lead to disciplinary action up to and including termination of employment.  If you believe that you are potentially involved in a situation that could create a conflict of interest and affect your ability to adequately perform your job with&#160;Cumberland, you should inform your direct supervisor and Cumberland&#8217;s Human Resources Department immediately.</font></div><div id="i948cd6629d6e40e8bea0cae6137ef94c_4"></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 14.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Debarment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You represent and warrant that you have not been debarred and will notify the Company immediately if you are debarred, pursuant to subsection 306(a) or 306(b) of the Federal Food, Drug, and Cosmetic Act.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 15.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Any notice required or permitted to be given under this Agreement shall be sufficient if in writing and if sent by registered or certified mail to your residence or to the Company&#8217;s principal office in the case of the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 16.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The waiver by either party of any provision of this Agreement shall not operate or be construed as a waiver of any subsequent breach.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 17.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Entire Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement contains the entire agreement of the parties and may not be changed orally, but only by an agreement in writing signed by the party against whom enforcement of any waiver, change, modification, extension, or discharge is sought.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 18.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Governance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement shall be governed by the laws of the State of Tennessee.  Any dispute arising out of this Agreement shall be resolved, at the Company&#8217;s sole option, by courts sitting in Nashville, Tennessee, and you waive any objection to such venue.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> 19.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Enforceability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If any provision of this Agreement shall be held by a court to be unenforceable, such provision will be enforced to the maximum extent permissible, and the remaining portions of this Agreement shall remain in full force and effect.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">20.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Survival</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding any termination of your employment, this Agreement shall survive and remain in effect in accordance with its terms.</font></div><div style="padding-left:3pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:3pt;text-align:justify"><font><br></font></div><div style="padding-left:3pt;text-align:justify"><font><br></font></div><div style="padding-left:1.5pt;padding-right:1.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">#   #   #   #</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This letter agreement may be signed in one or more counterparts, each of which shall be an original and all of which will constitute one and the same instrument.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:216pt;text-align:justify"><font><br></font></div><div style="padding-left:216pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Sincerely yours,</font></div><div style="padding-left:216pt;text-align:justify"><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> CUMBERLAND PHARMACEUTICALS INC.</font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">_______________________________________&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; By&#58;  &#160;&#160;&#160;&#160;A.J. Kazimi</font></div><div style="padding-left:252pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Chief Executive Officer</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Accepted as to all terms and conditions.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as of the 9th of March 2023&#58;</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">____________</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Todd Anthony</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">___________</font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Todd Anthony   </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140059958326464">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information Document<br></strong></div></th>
<th class="th"><div>Mar. 15, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 15,  2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CUMBERLAND PHARMACEUTICALS INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001087294<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">TN<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-33637<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">62-1765329<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">615<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">255-0068<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, no par value<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CPIX<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2525 West End Avenue, Suite 950<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">37203<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Nashville<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">TN<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>cpix-20230315_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="cpix-20230315.xsd" xlink:type="simple"/>
    <context id="i78615fa2d7f041369df685fcd4430c86_D20230315-20230315">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2023-03-15</startDate>
            <endDate>2023-03-15</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="i78615fa2d7f041369df685fcd4430c86_D20230315-20230315"
      id="f-22">0001087294</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="i78615fa2d7f041369df685fcd4430c86_D20230315-20230315"
      id="f-23">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="i78615fa2d7f041369df685fcd4430c86_D20230315-20230315"
      id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="i78615fa2d7f041369df685fcd4430c86_D20230315-20230315"
      id="f-2">2023-03-15</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="i78615fa2d7f041369df685fcd4430c86_D20230315-20230315"
      id="f-3">CUMBERLAND PHARMACEUTICALS INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i78615fa2d7f041369df685fcd4430c86_D20230315-20230315"
      id="f-4">TN</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="i78615fa2d7f041369df685fcd4430c86_D20230315-20230315"
      id="f-5">001-33637</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="i78615fa2d7f041369df685fcd4430c86_D20230315-20230315"
      id="f-6">62-1765329</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i78615fa2d7f041369df685fcd4430c86_D20230315-20230315"
      id="f-7">2525 West End Avenue, Suite 950</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i78615fa2d7f041369df685fcd4430c86_D20230315-20230315"
      id="f-8">Nashville</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i78615fa2d7f041369df685fcd4430c86_D20230315-20230315"
      id="f-9">TN</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i78615fa2d7f041369df685fcd4430c86_D20230315-20230315"
      id="f-10">37203</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i78615fa2d7f041369df685fcd4430c86_D20230315-20230315"
      id="f-11">615</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i78615fa2d7f041369df685fcd4430c86_D20230315-20230315"
      id="f-12">255-0068</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="i78615fa2d7f041369df685fcd4430c86_D20230315-20230315"
      id="f-13">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="i78615fa2d7f041369df685fcd4430c86_D20230315-20230315"
      id="f-14">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="i78615fa2d7f041369df685fcd4430c86_D20230315-20230315"
      id="f-15">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="i78615fa2d7f041369df685fcd4430c86_D20230315-20230315"
      id="f-16">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="i78615fa2d7f041369df685fcd4430c86_D20230315-20230315"
      id="f-17">Common Stock, no par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i78615fa2d7f041369df685fcd4430c86_D20230315-20230315"
      id="f-18">CPIX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i78615fa2d7f041369df685fcd4430c86_D20230315-20230315"
      id="f-19">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="i78615fa2d7f041369df685fcd4430c86_D20230315-20230315"
      id="f-20">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityEmergingGrowthCompany
      contextRef="i78615fa2d7f041369df685fcd4430c86_D20230315-20230315"
      id="f-21">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>13
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ X#QO5APX9>H_ 0  / (
M  \   !X;"]W;W)K8F]O:RYX;6R-4<MNPD ,_)75?D 34(M41+B4/I"J%I6*
M^Y)UB,4^(J\#+5]?)U%4I%YZ\GILC6=F%^=(QWV,1_7E74B%KIF;>9:EL@9O
MTDUL(,BDBN0-2TN'+#4$QJ8:@+W+IGD^R[S!H)>+D6M#V743&4K&& 3L@!W"
M.?W.NU:=,.$>'?)WH?NW ZT\!O1X 5OH7*M4Q_-+)+S$P,9M2XK.%7HR#'9
MC.4?>-N)_#3[U"-L]A]&A!1ZE@MAA92XW^CYC6@\@2P/7<OQ"1T#K0S#,\6V
MP7#H:,1%=F6CSV&L0XAS^D^,L:JPA%4L6P^!AQP)7"<PI!J;I%4P'@H]KB@3
MK'H,+"&I=1BH9+=S*J?7=G#-(O<J0YJC#&AM!^&C6@L5!K!O<B )+LF5&U)=
MZ7FFMW>3>TFH=>Y!L/?P&HT=S8\?M_P!4$L#!!0    ( . \;U8D'INBK0
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M;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ X#QO5CKI6M'O    *P(  !$
M             ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @
MX#QO5IE<G",0!@  G"<  !,              ( !S0$  'AL+W1H96UE+W1H
M96UE,2YX;6Q02P$"% ,4    " #@/&]6F4K#360$  "I$   &
M    @($."   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @
MX#QO5I^@&_"Q @  X@P   T              ( !J P  'AL+W-T>6QE<RYX
M;6Q02P$"% ,4    " #@/&]6EXJ[',     3 @  "P              @ &$
M#P  7W)E;',O+G)E;'-02P$"% ,4    " #@/&]6'#AEZC\!   \ @  #P
M            @ %M$   >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ X#QO
M5B0>FZ*M    ^ $  !H              ( !V1$  'AL+U]R96QS+W=O<FMB
M;V]K+GAM;"YR96QS4$L! A0#%     @ X#QO5F60>9(9 0  SP,  !,
M         ( !OA(  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&      D "0 ^
) @  "!0

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="cpix-20230315.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Document and Entity Information Document</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cumberlandpharma.com/role/DocumentandEntityInformationDocument</Role>
      <ShortName>Document and Entity Information Document</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="cpix-20230315.htm">cpix-20230315.htm</File>
    <File>ajkazimiemploymentagreemen.htm</File>
    <File>chrisbittermanemploymentag.htm</File>
    <File>cpix-20230315.xsd</File>
    <File>cpix-20230315_lab.xml</File>
    <File>cpix-20230315_pre.xml</File>
    <File>jameshermanemploymentagree.htm</File>
    <File>johnhammemploymentagreemen.htm</File>
    <File>toddanthony-employmentagre.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>18
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "cpix-20230315.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2021": 23
   },
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "cpix-20230315.htm"
     ]
    },
    "labelLink": {
     "local": [
      "cpix-20230315_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cpix-20230315_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "cpix-20230315.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd"
     ]
    }
   },
   "elementCount": 23,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 22,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "cpix",
   "nsuri": "http://cumberlandpharma.com/20230315",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20230315.htm",
      "contextRef": "i78615fa2d7f041369df685fcd4430c86_D20230315-20230315",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Document and Entity Information Document",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument",
     "shortName": "Document and Entity Information Document",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20230315.htm",
      "contextRef": "i78615fa2d7f041369df685fcd4430c86_D20230315-20230315",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>19
<FILENAME>0001628280-23-007952-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-23-007952-xbrl.zip
M4$L#!!0    ( . \;U97VN4+@1H  "B1   >    86IK87II;6EE;7!L;WEM
M96YT86=R965M96XN:'1M[5WK<]LVMO]^_PJL<[=-9F39\B-.[&QF'-N]23=)
M,W$ZF7[J0"0DH28)+D!:4?_Z>QX ">KA.&T36>YF$L>B2#P.SO-W#L!G_SC_
MZ>S#+^\NQ*3*,_'NYQ>O7YV)K>V=G8_[9SL[YQ_.Q<L/;UZ+@_[N0'RPLG"Z
MTJ:0V<[.Q=LML36IJO)X9V<ZG?:G^WUCQSL?WN]@4P<[F3%.]=,JW7K^#*_
M3R73Y__S[!_;V^+<)'6NBDHD5LE*I:)VNAB+CZER5V)[V]]U9LJ9U>-))?9V
M]_;%1V.O]+7D[RM=9>IY:.?9#G]^MD.=/!N:=/;\6:JOA4[_M:4/=Q\?'#T>
MR<='@\.#=#08/CG8/=H_.GQZH X/CP;[OPY@D#MP.S_CJEFF_K65ZV)[HK#_
MX\'A?G__<5F=3'5:38X'N[O_W.K<6ZE/U;;,]+@X3F \RL+7.A\+F570?R['
MZM?=_F_E>$LXF\Q?X29\5T]WRT\GN;1CZ'UHJLKDQX?0\;6RE4YDYCNA_OAK
M/Z;]IP?EIW@:SY^-3%$!+2Q<Y%_YNX6)+AO\BF>_\5/\77@V,9FQQP]VZ<\)
M?K,]DKG.9L???]"Y<N*MFHKW)I?%]ST'O+KME-4COM'IW]7Q8 \H21^G3.P#
M:"?3A6K6F1;VC;3)1#SM$=O=9B:_U:[2H]DMIG)KXG2;_.84L'UQVO^Q+_XM
M?]>Y%G=_Q(/'N[OBHW*5N"A2<7JMBEKUQ&6M*R4&^[N[=W\&;Z6;7.LL@V%_
M>"O$_M'>[E_&?.&Q4J8I*-KM3(VJ8U)HBPWQ)5VD()['VWC3F@CR7GWWX/#)
MR7</8&V7_+S(R\S,R(J8D3C],?"J=.)LHM5(7'Q225WI:R5^&HUTHJP8SL19
MG0^5S20PR;N)M+E,5$V*U8E71=+_JPE^9[CK7$D+1.K] 5'>D!E>C$8JH>7^
M41:UM#,Q8 W>$]5$.Y&I"LR-D&.K%''-PVJBQ'</GNSM[9Z<AJOT>7#R2$Q!
M%(6ZUB &B1)X*SR=.X&<DY@B)4?(B1KDQ(KI1(/%F)F:'QLJH8@[P;/Y/,]U
M!G)F\E(6LV88KPKLS<$PK,0>D=>A'YA'61I=5#23&U@>;L?6?;,]&KZ!*U:,
MC4GIX[7,:CG,5+>C'CUG5:)T6=%]KL8V-=!CALWRG(&PT)B"6<KDJC#33*5C
ME?+#I02?!1:82(Z#')DL,U-'8GUO^7#07Z6QPMB__:A8IZ<J,;RXQ\2V>-?6
M<V0-53BZWE_?$+>>"_&AY51F&B<J VSI!ZA(POXN?/10/EK%2,OI5,H9$0B4
MA!1.9J@"A])II)<5,(IKT A.E,K"YQQ5DW3P$V_'OZ S,V&1RB#<3G\2$V 2
M"S> ]K35;'N$:J6:F-JA,DAA":1UXN'_/CXZ[ $E^KN[CWHX!E(E&EJT$-O!
M'?"K^@^VG<.4)]D,+KA*9AEJ+H>]HZH8?!7&.^H_N8UPE(;#VF.K,HG:\Z0R
MY?'V07]O,?!"FK'<N&JMPI)*TL)*@A*&X:DB!0-/),;+:/?Z0OP "T]WS& I
M2"G#FHS D/4ZQJJ4.OWS;),JM) P4C)ZD=5!%M"PULX 9Z3:0="/Y ;Q?7HB
M2FO0R(+)F)BINE8T3(D6!^8W!)JSV0/^SN45#G7&C,.&ERS[)=I]N&< (L-S
M2A2,4=0E/DACZMI.U;J..$?L"NCB0/\)\=944UU-@$4+=)5I'G"3&H.U'?=$
M <83+^MB2=\0[2O@>&A2(]]7L"@H/X:_H*8DK"N.$$946[5L1*#?4@4TTD-X
M%KH)/>RS+8>6&V<%AGM_U=]PI?K[)?:S8*@:-0XI0!1572(SH@*"9?4<"#1/
M&Y],P7.%&B%' JW!CP(.;'GVA9$V15*?:W!^*F-=GPT3NW_-@E&_.M/5C)RC
MMF]<JS"Z,;1L(X$@9G?D.'K';'Y,H@0_T?5P9*X&P:6/P/HS;$[FS%$C:W)1
M ;5QUO2_9C7:"M><X_>]6S:Q^\L\R8W,X\G9\$Y0 D%?#4U1.URLL95YSRL\
MTB9>"TJ,"8#FN0)B@S8@EH"068,J0WUHAK]Q+,+Q0K00Z-@/CDY@_8$SP K&
M+4)/H%U8 32J%)__/(_.+3>P["G,@SB()Q,XLN40U//8>/C&U31H8JF8W4EK
ME64&1A!I-4>;SJT<$OCO I5SD^J1#ER+A@B[H/\]U\[9A;FY-!3[!@S<,E%_
M%UV'1<]@%0#LH=K=]A$YA'G5U>(C?P@EC'].;(OGC-7V$&S7U3:9]6.93>7,
M;7TQCGU[L#A 2 3,HY-TN!1%6I?@IY^W&A33@B\K!; IHT<W1.@0?8!7!?,P
MR17XM[5U-3Z$1ITO"E,R%! A"Y<_G3X"&;Q$^7/0H'*KQ SN;%0$RY%3Y)6
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MI*4>W:!J%53*'%'-]4?''D34;P<>=]]P>7HSFWMML@!_+.QY7!<0XB+]\15
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M.E]HCXW"_,D]7P<S-=B B2JENV9AQ";=@JF>0^*& 6'F_BC*$C.Y>3CVHH'
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MC4U_BY=+7PNPZ8KCW;_OBO^3O^NYOB*5'AX$MMX^X)[,L"CIC+I+H47T$S=
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M 3I0?ZM^%GK#.6O4Y?=>PP8F,@$]1+3KLJ1!UQ<P=\WV79<&(6LD?YPF"*!
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M]M>01R-"'ZF8S6%!S[B!2/Q ANWC4$)_30L@G\?530@YX7CO.AV=ID(AW$6
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M![(/4E=6<O-.GAD$;/$16<"AL 4/%.#$.U8K^"LM]"_P)L;7B,$+7& V$N)
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MPKY#ZPU.=E=X]7MKS8-@=3LF@S]02P,$%     @ X#QO5AHOG*1\"@  25X
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M;Z0A))ZD\D7-.&XG)2MGL)V>T5IF24\6FN)BG2^JGE#H'(.'Y ,N+9,S0LP
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M4YEIG&@,L*6?H"*@^:OPT3UY?Q,CK:?37"Z)0("54CA9HB882Z>17E; +"X
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M 3LF8 \X/G2)!PYF-9@,L Z3GV=BWEK7XDVHL?A#8>;LZB>1@P\_'M\'!ON
MS.7@@<IMXB&X,O(_,XE3I'*!R_W>ZQJ#VSCC//%!"/9ZX06X%M@5-*9< !>H
M B;@)1FPLEG++P.VRCK:%(7/8_#3B'>#[(.M"IB>^6'7+TQ;5-' $)2\B*3I
MA/V25;G+EW5[(5EM9-ZS3[F:D^'38X]@^!QD/6,26 [M)]/@OI1:>N6/]FS
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M\-!Q(Q1 ]"U\'AF>X(73]3#@=4YJQ 'R1Q<7?88<2%G0-^@%LHGNT60X_LR
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M3G/58R^4FM$=M0371>+&!*>=BN30#89M*#@*3*F4%C<!_@JH:U%J.<#,ECH
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M>6UE;G1A9RYH=&U02P$"% ,4    " #@/&]6R8:T'",4  !;I@  $0
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M;WEM96YT86=R965M96XN:'1M4$L! A0#%     @ X#QO5L@(%HHZ&0  XH4
M !X              ( !^(\  '1O9&1A;G1H;VYY+65M<&QO>6UE;G1A9W)E
:+FAT;5!+!08     "0 ) ( "  !NJ0     !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
